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ABSTRACT

Transcriptional Regulation of HLA-E by Interferon Gamma in Tumor Cells

A dissertation in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University

Quintesia Grant
Virginia Commonwealth University, 2010

Advisor: Gordon Ginder, M.D., Professor, Departments of Internal Medicine and
Microbiology/Immunology

The human Class Ib gene, HLA-E inhibits both Natural Killer Cells and a subset of
CD8+ cytotoxic T lymphocytes by engaging the CD94/NKG2A inhibitory receptor. IFN-γ
induces the expression of HLA-E as well as Class Ia molecules, which are required for
the killing of target cells. Since HLA-E has negative effects on immune killing of target
cells, we have sought to identify locus specific mechanisms of IFN-γ induction in order
to identify molecular targets for selective activation of Class Ia genes, but not HLA-E.
We have previously identified a unique upstream IFN-γ response region in the HLA-E
promoter and showed that GATA-1 is required for its function in the K562 leukemic cell
line. We have now examined the effect of GATA family members on IFN-γ induction of
HLA-E in other cell types. HLA-E CAT reporter gene assays

xii

demonstrate that tumor cells that express GATA factors as determined by western blot
and quantitative PCR, mediate a 2.4 to 4.0 fold enhanced response to IFN-γ stimulation.
Functional constructs containing mutations of the core nucleotides in the GATA binding
site had a 4.8 fold decreased response to IFN-γ in A2780 cells and a 8.5 to 14.0 fold
decreased response to IFN-γ in SKOV3 cells. Knockdown of GATA-6 using siRNA
resulted in a 40% decrease in HLA-E induction in Seg1 cells and a 30% decrease in
HLA-E induction in HCT116 cells. Tetracycline regulated shRNA knockdown of GATA-6
expression in the SKOV3 cell line revealed a 3 fold decrease in the IFN-γ response of
HLA-E reporter driven constructs. Additionally we observed a decreased IFN-γ
response in SKOV3 cells transfected with siRNA specific for CBP and IRF-9. We
conclude that GATA factors play a tissue specific role in regulation of IFN-γ mediated
HLA-E expression and that IRF-9 may be a target for the differential manipulation of
classical MHC and HLA-E.

xiii

Chapter 1: Introduction

Major Histocompatibility Complex
The Major Histocompatibility Complex is a generic term given to a number of genes,
located on chromosome six, that determine the fate of grafted tissues. The highly
polymorphic nature of the classical MHC loci ensures diversity in MHC gene expression
of the population as a whole (Parham, Lawlor, Lomen, & Ennis, 1989). Most of the
genes in the MHC family are involved in immunity, including the MHC class I loci, which
can be divided into classical and nonclassical subdivisions(Gobin, Keijsers, van
Zutphen, & van den Elsen, 1998; Howcroft & Singer, 2003; van den Elsen, Gobin, van
Eggermond, & Peijnenburg, 1998). The function of Class I molecules is to present
foreign peptide antigens to T cells. Both the classical and nonclassical MHC genes
encode integral membrane proteins called class I heavy chains, which are comprised of
three globular domains (α1, α2, and α3), a transmembrane region, and a cytoplasmic
domain (Parham et al., 1989; Williams, 2001). The α1 and α2 domains form the
peptide binding cleft of MHC. This region interacts with peptides processed by the
cytoplasmic proteasome complex that are eight to ten amino acids in length.
Interestingly, the peptides that bind to a particular allelic form of MHC have been shown
to exhibit common features, such as a hydrophobic residue at position two or a
positively charged residue at position nine (Cunningham, 1977).
All MHC molecules must associate with beta-2 microglobulin in order to be expressed
on the cell surface (Peterson, Rask, & Ostberg, 1977). The interaction between the two
molecules occurs via the α3 domain as does the interaction between MHC and the CD8
1

molecule present on cytotoxic T lymphocytes. The members of the classical or Class Ia
are HLA-A, HLA-B, and HLA-C in humans and H-2K, H-2D, and H-2L in mice. As
stated previously, Class Ia genes are diverse and highly polymorphic. For example
there are several hundred HLA-A, B, and C alleles (Williams, 2001). Furthermore, it has
been observed that alleles differ in the ability to bind peptides. It is important to note that
if a peptide cannot be bound by any of the Class Ia alleles, it will render that peptide
non-antigenic as there will be no corresponding T-cell that can recognize it. Class Ia
molecules are present on the surface of most nucleated cells.
In contrast, Class Ib MHC, whose members are HLA-E, HLA-F, and HLA-G in humans
and Qa-1 in mice, show limited polymorphism. For example there are only six HLA-E
alleles, nineteen HLA-F alleles, and fifteen HLA-G alleles that have been discovered to
date (Ishitani, Sageshima, & Hatake, 2006; Kamishikiryo & Maenaka, 2009; Pyo et al.,
2006). Since bound peptide is a requirement for expression of Class I molecules on the
cells surface it is likely this low expression is due to a limited amount of peptides that
can be recognized and presented by these molecules. Additionally, both HLA-F and
HLA-G exhibit limited tissue distribution, while HLA-E is ubiquitously expressed (Gobin
& van den Elsen, 2000). Interestingly, all three class Ib molecules have been identified
at the maternal-fetal interface, suggesting that these molecules may have evolved as a
method of immunotolerance (Copeman et al., 2000; Gobin & van den Elsen, 2000;
Ishitani et al., 2006).
HLA-E
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The Class Ib molecule, HLA-E functions as a sentinel molecule for Class Ia expression.
It has been shown to bind to the nonameric leader peptides of Class I molecules. After
synthesis, the Class I preprotein is cleaved by signal peptidase before being further
processed by signal peptide peptidase and transported into the endoplasmic reticulum
lumen via the TAP transporter (Borrego, Ulbrecht, Weiss, Coligan, & Brooks, 1998; V.
M. Braud, Allan, Wilson, & McMichael, 1998). Here a newly formed HLA-E molecule, in
conjunction with a beta-microglobulin molecule binds to the leader peptide.
Furthermore, HLA-E has been shown to bind strongly to the HLA-A2 sequence,
VMAPRTLV, with the key residues required for peptide binding being located at position
2 and position 9 of the leader peptide (V. Braud, Jones, & McMichael, 1997). Although
the leader peptides of Class Ia molecules are most often presented by HLA-E
molecules, it has recently been discovered that HLA-E can bind gene products from
cytomegalovirus, Mycobacterium tuberculosis, and Epstein Barr virus (V. M. Braud,
Tomasec, & Wilkinson, 2002; Heinzel et al., 2002; Pietra et al., 2003; Ulbrecht et al.,
2000). Additionally, HLA-E can bind to mimic HLA Class I leader peptides produced by
CMV, resulting in immune evasion (Llano, Guma, Ortega, Angulo, & Lopez-Botet, 2003;
Ulbrecht et al., 2000).
HLA-E binds avidly to the C-lectin type receptor NKG2A/CD94, which is also found on
certain types of cytotoxic T-cells (Lee et al., 1998) . Furthermore, a knockout mouse
model of the murine homologue of HLA-E, Qa-1, has been shown to play a key role in
the development of CD8+ T suppressor cells (Wang, Ramaswamy, Hu, & Cantor,
2001). Recent evidence also shows that in some instances HLA-E has the ability to
stimulate cytotoxic activity via the interaction with the T-Cell Receptor on CD8+ T cells
3

(Romagnani et al., 2002). Although HLA-E has the ability to behave as a positive
regulator of the immune system in specific circumstances, its primary action is to inhibit
the cytotoxic activity of both natural killer cells and CTLs, thereby mediating an opposite
effect on the immune system in comparison to Class Ia molecules.
Interaction of MHC Class I and Natural Killer Cells
MHC molecules interact with cells from both the innate and adaptive immunity. Class Ia
molecules are critical for CD8+ Cytotoxic T cell development, as well as the recognition
and killing of target cells. Additionally, Class Ia molecules have been shown to interact
with Natural Killer Cells via their Killer Inhibitory Receptors (KIRs) which results in
blockade of Natural Killer Cell activation and cytolytic function (Lanier, 1998; Moretta &
Moretta, 2004). NK cells are an integral component of innate immunity as their activity
not dependent on prior sensitization to antigen or clonal expansion. This inhibition by
Class I molecules provides protection to normal cells from NK activity, while at the same
time sensitizing the NK cells to compromised or decreased Class I expression. Recent
studies show that the activity of NK cells may be contigent on prior interaction with selfMHC before the cells are “licensed to kill” (Yokoyama & Kim, 2006). Specifically,
authors postulated that NK cells would have a reduced capacity to recognize and kill
non-self virally infected or transformed tissues prior to being educated on what
designated a tissue as “self.”
Interaction between HLA-E and NK cells has also been described. In fact HLA-E is the
principal ligand for the inhibitory CD94/NKG2A receptor (Lee et al., 1998; Vales-Gomez,
Reyburn, Erskine, Lopez-Botet, & Strominger, 1999). HLA-E binds and presents the
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leader peptide of other class I molecules such as HLA-A, B, C and G (Pietra,
Romagnani, Moretta, & Mingari, 2009). As such its presence is indicative of global
Class I expression. The inhibitory action of both CD94/NKG2A and Killer Inhibitory
Receptors is mediated by immunotyrosine-based inhibitory motifs (ITIMS) located in the
cytoplasmic tails of the molecules. It is also important to note that HLA-E has the ability
to engage the activating receptor CD94/NKG2C (V. M. Braud et al., 1998; Vales-Gomez
et al., 1999). However it seems that the molecule is preferably bound by NKG2A as it
has a higher affinity for this receptor.

Figure 1. Effect of MHC on NK cell function. Interaction of MHC class I molecules with the KIR
receptors results in the inhibition of NK cell lysis of target cells. Loss of MHC class promotes
cytolysis. (arthritis-research.com/.../figures/ar1034-1.gif)

5

Interferon Gamma
Interferon gamma is a 48 kilodalton homodimeric glycoprotein that was first discovered
by EF Wheelock in 1965 (Boehm, Klamp, Groot, & Howard, 1997). He observed that a
substance in the supernatant of phytohemagglutinin stimulated lymphocytes was able to
inhibit the cytopathic effects of the Sindbis virus (Wheelock, 1965). Later this molecule
was labeled as the type II interferon with special

Figure 2. Type I and Type II Interferon Signaling. Adapted from Stark et al. Jak-STAT Pathways and
Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins. Science. 1994; 264:
1415-1421.
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emphasis being placed on its immune function. Interferon gamma is principally
produced by cytotoxic T-lymphocytes, CD4+ T helper 1 cells, and Natural Killer cells
(Darnell, Kerr, & Stark, 1994). Secretion of the molecule is stimulated by ligation of the
T-cell receptor or in response to the cytokine interleukin 12 that is produced by
macrophages. Interferon gamma has a number of functions including control of viral
infection, increasing expression of MHC genes, enhancing the respiratory burst,
apoptosis, and regulation of leukocyte adhesion to the endothelium (Boehm et al.,
1997). Interferon gamma has also been implicated in the differentiation of naïve T
helper cells into Th1 cells which are critical for cellular immunity.
The importance of IFN gamma is demonstrated by knockout studies of the cytokine and
or its receptor in mice. Unchallenged mice show phenotypic changes specifically in
lymphoid cells. Once challenged the mice show a particular deficiency in responding to
intracellular pathogens, specifically Mycobacterium, Listeria monocytogenes, and
Leishmania major (Lu et al., 1998). These mice are also more susceptible to infection
with vaccinia virus (Xu, Johnson, Liggitt, & Bevan, 2004). When challenged with
Mycobacterium, interferon gamma deficient mice are capable of developing granulomas
but are unable to produce the reactive oxygen species which are necessary to clear the
pathogen (Flynn et al., 1993). Additionally mice that are null for the interferon gamma
receptor died within nine weeks after infection with the BCG strain of Mycobacterium
bovis, whereas infection in wild type mice was not fatal (Erb,K.J. 1999). Interferon
gamma null mice are also highly susceptible to Listeria monocytogenes (DiTirro et al.,
1998; Lu et al., 1998). Further characterization of these mice showed that cells were
unable to induce B-cell class switching to IgG2a, produced lower amounts of interferon
7

gamma in response to antigenic challenge and was unable to activate JAK-Stat
signaling in response to interferon gamma. These studies demonstrate the importance
of interferon gamma for enhancing the activity of macrophages.
Interferon gamma signaling is activated when the cytokine binds to its heterodimeric
receptor IFNGR. This interaction results in a conformational change that culminates in
the transphosporylation by the associated Janus kinases, JAK 1 and JAK 2 (Darnell et
al., 1994). Specifically, JAK1 is associated with IFNGR1 and JAK2 is associated with
IFNGR2. The phosporylated residues then serve as docking sites for STAT1 alpha
molecules via the SH2 domain. The subsequent phosphorylation of the STAT 1
molecules on tyrosine 701 leads to dissociation from the receptor and homodimerization
(Boehm et al., 1997). Specifically, the molecules associate via the SH2 domain of one
STAT1 alpha molecule and the phosphorylated tyrosine residue of the other. The newly
formed homodimer translocates into the nucleus and then binds to the gamma
activation site of interferon stimulated target genes.
Stat 1 alpha is the principle molecule involved in interferon gamma signal transduction.
This fact is illustrated by STAT1 knockout mice which exhibit similar deficiencies as
interferon gamma or interferon-gamma receptor null mice (Levy & Darnell, 2002). STAT
1α is a 91 kD protein, which like the other members of the STAT family, consists of six
conserved domains: n-terminal domain, coiled-coiled domain, DNA-binding domain,
linker domain, Src-homology (SH2) domain, and transcriptional activation domain
(Brierley & Fish, 2005). The amino terminal domain is critical for stabilizing homodimer
or heterodimer formation. The coiled-coiled domain is critical for protein interactions,
such as that of STAT 1α and STAT2 with interferon regulatory factor nine (IRF-9). The
8

Src-homology domain (SH2) is important for dimerization and receptor binding. The
transcriptional activation domain, mediates interactions with nuclear coactivators and
histone acetyltransferases (Brierley & Fish, 2005).
Additionally, the transcriptional activation domain contains two residues that are critical
for STAT function. There is a conserved tyrosine residue that is absolutely required for
STAT activation as its phosphorylation permits interaction with the SH2 domain of other
STAT molecules as well as a conserved serine residue whose phosphorylation is
necessary for full transcriptional activity (Levy & Darnell, 2002; Shuai, Stark, Kerr, &
Darnell, 1993). In fact loss of serine phosphorylation as a result of pharmacologic
inhibition of Protein Kinase C-delta, causes a decrease in the association between
STAT molecules and p300. STAT1 is able to interact with p300 via the transcriptional
activation domain and the n-terminal domain (J. J. Zhang et al., 1996). Interestingly, the
ability of STAT1 alpha to transactivate genes is inhibited after incubation with the
adenovirus E1a protein and after pharmacologic inhibition of histone deacetylase
activity. Furthermore, Stat 1β is a 84 kD protein that is derived from the same gene as
Stat 1α. Differential splicing results in a shorter c-terminus than the Stat1a molecule and
as a result, Stat1b has the ability to bind DNA but is unable to transactivate genes
(Brierley & Fish, 2005).
STAT1 homodimers bind the Gamma Activation Site (GAS), a nine base pair
palindromic sequence (TTNCNNAA) first described in regards to the transcriptional
activation of the guanylate binding protein (GBP) gene (Decker, Lew, Mirkovitch, &
Darnell, 1991). The interaction of STAT molecules with its consensus region has been
shown to be increased by the cooperative binding of adjacent homodimers. In fact, two
9

STAT1 homodimers bind to the Interferon Response Region (IRR) of the HLA-E
promoter (Gustafason K 1996). Mutagenesis studies demonstrate that lysine 366,
aspartate 421, and arginine 460 are crucial for STAT1 binding in response to Interferongamma (Yang, Henriksen, Schaefer, Zakharova, & Darnell, 2002).
In addition to the Gamma Activation Site, STAT1 has also been shown to interact with
the Interferon Stimulated Response Element (ISRE). The consensus sequence
AGTTTCNNTTTCC/A is bound by Interferon Stimulated Gene factor 3 (ISGF-3), which
consists of STAT1, STAT2, and Interferon Regulatory Factor 9 (Bluyssen et al., 1995;
Waring, Radford, Burns, & Ginder, 1995). Studies demonstrate that IRF-9 recognizes
and binds to the ISRE while STAT1 interacts with flanking sequences (Wesoly,
Szweykowska-Kulinska, & Bluyssen, 2007). It is important to note that ISGF3 formation
is a consequence of type I interferon signaling. In the case of most HLA Class Ia
genes, IFN- induces the Interferon Response Factor-1 (IRF-1) transcription through its
gamma activation sequence (GAS) sequence, thereby allowing the IRF-1 protein to
stimulate HLA-B or HLA-C transcription through binding to the Interferon Stimulated
Response Element (ISRE). Additionally, some studies show that a STAT1 homodimer
in conjunction with IRF-9 is capable in binding to the ISRE in response to IFN-γ.
Interferon Response Region and Upstream Interferon Response Region of the
HLA-E promoter
The promoter of HLA-E differs significantly from that of Class Ia genes. Class Ia
molecules have increased expression as a result of both Interferon-alpha, beta as well
as interferon-gamma via the interferon stimulated response element. HLA-E
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transcription is also induced by interferon gamma, although the HLA-E promoter does
not contain a functional ISRE. Kuluski and colleagues reported the insertion of Alu
elements and Charlie fragments within the enhancer and proximal promoter regions of
HLA-E and postulated that these insertions contributed to the deletion of the enhancer A
region and the ISRE that is present in Class Ia promoters (Kulski et al., 1998; Kulski,
Shigenari, Shiina, & Inoko, 2010). Indeed it has been shown via electrophoretic mobility
shift assays (EMSA) and reporter gene assays that the putative enhancer A and ISRE
regions of HLA-E do not bind IRF-1 or NFkB and that these factors are incapable of
transactivating the HLA-E gene.
Furthermore it has been demonstrated that the response to interferon gamma is
mediated by a unique response element in the HLA-E promoter, termed the Interferon
Response Region (IRR). The region extends from -193 to -146 and is composed of an
extended, imperfect repeat consisting of two distinct half sites. The 5’ half is
homologous to a gamma activation site (GAS), while the 3’ half is similar to the ISRE.
Gel mobility shift assays using probes containing a duplication of the 5’ half or the 3’ half
of the IRR bound IFN-γ induced complexes that exhibited the same mobility as the IFNγ activation complex that bound the intact IRR. The observation of a symmetric
methylation interference pattern in conjunction with the binding of STAT1 alpha to the
IRR on EMSA led to the conclusion that a STAT1 alpha homodimer bound the IRR and
helped to mediate the transcriptional response to Interferon gamma (Gustafason, K
1996).
Further experiments suggested that additional factors could be a part of the activating
protein complex that binds the interferon response region in addition to STAT 1α.
11

Treatment of U937 nuclear extracts with the minor groove binding drugs Netropsin and
Dystamicin A inhibited the formation of IRR-AC and IC substitution of the AT rich portion
of the IRR further demonstrated that minor groove contacts were required for full
induction of HLA-E by IFN- γ. Specifically, a minor groove binding protein, HMGA1, has
been implicated as part of the complex. Purification of the protein complex led to the
verification of the STAT1 alpha molecule in the IRR-AC and suggested that the
polypyrimidine tract binding protein, PSF, may be a part of the complex (unpublished
results).
Characterization of HLA-E induction in K562 leukemia cells led to the discovery of the
Upstream Interferon Response Region (UIRR). This element is located 38 base pairs
immediately upstream of the IRR and is dependent on the IRR for its function. Analysis
of this region of the promoter with MATInspector software demonstrated a
nonconsensus GATA transcription factor binding sequence. Subsequently, it was
shown that when the UIRR is bound by GATA-1 in K562 cells, a five-fold enhanced
transcriptional response to IFN-γ can be achieved. (Barrett,DM 2004). However it is
important to note that this enhanced response was not observed in the U937 cell line.
Therefore other cell lines were examined for their ability to promote UIRR function. We
observed that those cell lines that expressed a GATA transcription family member also
demonstrated an enhanced transcriptional response to IFN-γ via the UIRR. These
observations led to the hypothesis that there is a cell-type restricted upstream enhancer
element present in the HLA-E promoter that can be bound by various GATA
transcription family members.
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UIRR AND IRR ELEMENTS OF HLA-E

-231

“GAS-like”

GATA
site

“ISRE-like”

-193

-146

GAGTGTGCAGAGATACCGAAACCTAAAAGTTTAAGAAC TGCTGATTGCTGGGAAACTCTGCAGTTTCCCGTTCCTCTCGTAACCTG

UIRR

IRR

Figure 3. Diagram of UIRR and IRR elements in the HLA-E promoter. Highlighted
region in the UIRR denotes the GATA binding element. Highlighted portions of the IRR
region denotes the 5’ and 3’ half sites which are similar to the Gamma Activation Site and
Interferon Stimulated Response Element.
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GATA Transcription Factors
The development of differentiated cell types from multipotent progenitor cells is
mediated by the binding of transcription factors to cis regulatory elements in their target
genes or by the repressing the expression of genes which promote alternate cell fates.
GATA transcription factors play an essential role in the differentiation and development
of cells. The first GATA transcription family member to be discovered and investigated
was GATA binding protein 1 (GATA-1). It was discovered due to its ability to bind to the
3’ region of the human β globin gene (Lowry 1999). Subsequently five more
transcription family members were discovered. The GATA transcription family members
can be divided into two subgroups based upon their tissue distribution and subsequent
roles in cell differentiation. GATA-1, GATA-2, and GATA-3 are characterized by their
role in hematopoetic cell fates. GATA-4, GATA-5, and GATA-6 are linked to the
development of mesoendodermal tissues such as heart, lung, pancreas, gonads, and
intestines. GATA binding proteins have also been identified in other species such as
C.elegans (ELT-1), Aspergillus (areA), Neurospora (nit-2), S. cerevisiae (DAL 80),
S.pombe (GAT-2), and Drosophila (pannier and serpent) (Dorfman 1992, Lowry 1999).
. The GATA family of transcription factors were named based on their ability to bind to
the DNA consensus sequence WGATAR or (A/G)GATA(A/G (Patient & McGhee, 2002)
Although the family members share common structural features such as an N-terminal
transactivation domain and two C-terminal zinc fingers DNA binding domains, they
exhibit less homology at the amino acid level (Lowry & Atchley, 2000). For example
GATA-2 and GATA-3 are 55% homologous, GATA-3 and GATA-4 are 20% homologous
(Maeda, Kubo, Nishi, & Futai, 1996). All family members exhibit an 80% homology at
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the zinc finger regions which consist of CX2-CX17-CX2-C (Molkentin, 2000; Simon,
1995). The C-terminal zinc finger is the primary DNA binding element of the GATA
protein, whereas the N-terminal zinc finger participates in protein-protein interaction and
stabilization of C-terminal binding. Pedone et al also demonstrated that the N-terminal
zinc finger has the ability to bind to DNA in the case of GATA-2 and GATA-3 but not the
other family members. GATA-2 and GATA-3 have also been shown to recognize the
GATC sequence equally as well as the GATA sequence (Ko 1993).
GATA-1 was identified based upon its ability to bind to the human β globin locus control
region. It was previously known as Eryf-1, NF-E1, NF-1, and GF-1. In addition to its
role as an erythroid cell regulator, GATA-1 also plays a role in Sertoli cell and eosinophil
development (Hirasawa 2002). GATA-1 null mice die in utero at approximately
embryonic day 10 from severe anemia and exhibit arrest of erythroid maturation. There
are several instances where GATA-1 mutations have been linked to human disease.
The R216Q missence mutation in the N-terminal zinc finger causes X-linked
thrombocytopenia with thalassemia (Lowry 2006). Mutations within the transactivation
domain of GATA-1 have been linked to the development of transient myeloproliferative
disorder (TMD) and acute megakaryoblastic leukemia.
GATA-2 is expressed in erythroid cells, fibroblasts, endothelial cells, embryonic brain,
and adult kidney (Dorfman 1992). Furthermore the expression of GATA-2 is required for
the survival of pluripotent hematopoetic stem cells. Interestingly, GATA-1 and GATA-2
are reciprocally expressed during erythropoesis with GATA-2 levels declining as GATA1 levels increase (Shivdasani 1997). Also, both GATA-2 and GATA-3 are required for
megakaryopoesis (Chang 2002). Recently, an interplay between C/EBP α and GATA-2
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expression during basophil development has been demonstrated. Arinobu et al
conducted experiments where they introduced GATA-2, C/EBPα or both into common
lymphoid progenitor cells and determined that expression of GATA-2 or C/EBPα alone
resulted in development of mast cells or granulocytes and monocytes, respectively.
However, overexpression of GATA-2 followed by C/EBPα resulted in pure basophil
colonies, whereas C/EBP α followed by GATA-2 promote a mixed myeloid population
(Arinobu 2009). Like GATA-1 null mice, GATA-2 knockout mice die at embryonic day
10.5 from severe anemia and exhibit reduced numbers of erythroid cells.
GATA-3 is an important transcription in the regulation of target genes. Interestingly,
GATA-3 plays a role in the expression of the NKG2A ligand, which is the receptor for
HLA-E (Marusina, Kim, Lieto, Borrego, & Coligan, 2005). GATA-3 is expressed in T
cells and plays a critical role in Th2 development (Ho, Tai, & Pai, 2009; Okazaki,
Maeda, Chiba, Doi, & Imai, 2009). Once again there is an antagonistic or concentration
dependent mechanism at work between a GATA transcription family member and
another transcription factor. In this case Tbet and GATA-3 have opposing roles in the
differentiation of T cells. T-bet induces the Th1 genetic program while GATA-3 induces
the Th2 phenotype. Specific deletion of GATA-3 in CD4+ T cells causes cells to
develop in Th1 cells ((Ho et al., 2009). GATA-3 has recently been shown to play a role
in embryonic mammary tissue morphogenesis and maintenance of the differentiated
state in adult luminal epithelial cells. Expression of GATA-3 is detected in estrogen
receptor positive breast cancers and several groups have shown that GATA-3 is a
positive regulator of estrogen receptor alpha (ERα) (Mehra 2005, Garcia-Closas 2007,
Voduc 2008, Eeckhoute 2007). Furthermore loss of GATA-3 expression has been
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shown to promote epithelial-mesenchymal transition (EMT), where an epithelial tumor
devolves into a more invasive fibroblast like tumor (Yan 2010 and Chou 2010). Pandolfi
et al (1995) reported that GATA-3 null embryos die between E11 and E12. These mice
show an aberration in fetal liver hematopoesis and deformities in the brain and spinal
cord. Furthermore, mutated GATA-3 in humans has been linked to HDR syndrome,
which consists of a constellation of symptoms which includes hypoparathyroidism,
sensorineural deafness, and renal dysplasia (Van Esch 2000).
GATA-4 is expressed in the heart, gut, gonads, liver, visceral endoderm, and parietal
endoderm (Molkentin 2000). GATA-4 is one of the earliest transcription factors
expressed in cardiac cells (Pikkarainen 2004) and continues to be expressed in the
adult. GATA-4 null mice die between embryonic days 8.0 and 9.0 due to cardiac
defects (Molkentin 2000). GATA-4 deficient mice exhibit an increase in GATA-6
expression, suggesting that it is a negative regulator of GATA-6 (Morrisey 1998).
Mutations of the GATA-4 protein can be associated with disease in humans. GATA-4
haploinsufficiency has been linked to atrial septal defects and congenital heart disease
(Pehlivan 1999 and Garg 2003).GATA-4 expression has been detected in the granulosa
and theca cell tumors of the ovary and high levels of GATA-4 has been shown to
correlate with risk of disease recurrence ( Laitinen 2000 and Kyronlanti 2008). Capochichi et al report that ovarian carcinomas that arise from epithelial cells lose expression
of both GATA-4 and GATA-6 due to promoter hypermethylation, which leads to deficient
expression of molecules that are important for cellular differentiation, such as collagen
IV, Dab-2, and laminin (2003).
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GATA-5 is expressed in the embryonic heart, lungs, urogenital ridge, bladder, and gut
epithelium. However during adulthood expression in the heart is lost (Pikkarainen
2004). GATA-5 null mice, which are viable, show no cardiac defects but do exhibit
genitourinary malformation (Viger 2008). Additionally, loss of GATA-5 expression via
promoter hypermethylation has been implicated in pancreatic cancer development and
gastric carcinoma (Fu 2007).
GATA-6 is expressed during development in the visceral endoderm, heart, lungs,
urogenital ridge, vascular smooth muscle cells, and in the gastrointestinal tract
(Molkentin 2000). Its expression in retained during adulthood in these tissues although
its expression is decreased in the liver and lungs. GATA-6 deficient mice die at
embryonic day 6.5 to 7.5 due to problems with lung development (Morrisey 1998).
Interestingly, GATA-6 null mice also exhibit a down regulation in GATA-4 gene
expression (Morrisey 1998). It has been demonstrated that GATA-6 has the ability to
bind to a wider range of DNA sequences than the other GATA transcription family
members. Sakai et al showed via polymerase chain random site selection that GATA-6
has the ability to bind to the GATT and GATC sequences in addition to the GATA
sequence, as long as an adenine is located at both ends of the sequence, thus
AGAT(A/T/C)A (1998). GATA-6 expression has been detected in malignant
mesothelioma and metastatic pulmonary adenocarcinoma where it was shown that
tumors that expressed GATA-6 resulted in a better prognosis than those with no GATA6 expression (Lindholm 2009).
Interferon Regulatory Factors
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The interferon regulatory factor family consists of nine transcription factors: IRF-1, IRF2, IRF-3, IRF-4/PIP/LSIRF/ICSAT, IRF-5, IRF-6, IRF-7, IRF-8/ICSBP and IRF-9/ISGF3γ
(Savistsky D 2010). The IRF family members were first described due to their
interaction with interferon inducible genes. In fact, the founding member of the IRF
family, IRF-1, was identified based upon its ability to bind to the IFN-β gene promoter
and cause transcriptional activation (Reis,L.F. 1992; Taniguchi,T. 2001). Analysis for
transcription factors with sequence similarity to IRF-1 led to the discovery of IRF-2,
which acts as a repressor of interferon α/β. The expression of IRF-1, IRF-2, IRF-7, and
IRF-9 is induced by viral infection or interferon stimulation. The core DNA sequence
recognized by IRF family was initially defined as 5’-GAAA-3’. Crystal structure analysis
between IRF-2 DNA binding domain and tandem repeats of GAAA sequence further
defined the IRF recognition sequence as 5’-AANNGAAA-3’ (Fujii,Y. 1999). This
sequence is strikingly similar to the ISRE (5’-A/GNGAAANNGAAACT-3’), which
explains why IRF factors can interact with the ISRE element in Classical MHC
promoters in response to IFN-α/β (IRF-9) or IFN-γ (IRF-1). All IRF family members
contain a well conserved N-terminal DNA binding domain that consists of five
tryptophan rich repeats, while the C-terminal region mediates protein-protein interaction
(Taniguchi,T. 2001).
Clinical Significance
Cancer immunotherapy attempts to use the specificity of the immune system to help
with the treatment of malignancy. Most human cancers are currently incurable unless
they are discovered and surgically removed at an early stage. The use of
immunotherapy approaches could potentially serve to help control the spread of
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cancerous cells and to facilitate the destruction of transformed cells that are resistant to
chemotherapy. Current biological therapies include passive antibody transfer, tumorspecific vaccines, and adoptive immunotherapy (Blattman & Greenberg, 2004). While
these treatment methods have proven to be successful clinically, there has been limited
success with cell-mediated immunotherapy. An example of successful treatment using
cell-mediated therapy is illustrated by the use of allogeneic bone marrow transplantation
to treat chronic myeloid leukemia. This method takes advantage of the graft-versustumor response in order to eliminate cancer cells (Dermime et al., 1997). Other
attempts to use immunotherapy without taking advantage of allo-reactive mechanisms
have proven more challenging primarily as a result of tumor immune evasion
mechanisms.
Transformed cells use a variety of methods to hamper the immune system including
physical exclusion of immune cells, disruption of the function of natural killer and NK-T
cells, and down-regulation of MHC Class Ia expression. Defective class Ia expression
is a common occurrence in human tumors such as breast cancer, prostate cancer, and
melanoma (Gasparollo et al., 2001; Maleno, Lopez-Nevot, Cabrera, Salinero, & Garrido,
2002; Maleno et al., 2004; Palmisano et al., 2001). The deficient expression often
involves a specific locus or allele and studies have shown that even minute changes in
HLA-A2 expression have a negative impact on the tumoricidal activity of CTLs
(Gasparollo et al., 2001). Furthermore some transformed cells use molecular mimicry
to escape immune recognition by creating peptides that are similar to the leader
peptides of HLA Class Ia molecules, which are presented by the HLA-E molecule and
inhibit the activity of natural killer cells. In these instances, the lack of HLA-E
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expression results in a negative impact on both cytotoxic T-lymphocytes as well as
natural killer cells. Since HLA-E serves a ligand for the NKG2A/CD94 receptor that is
present on many natural killer cells, NK-T cells, and a subset of CD8+ T cells, the ability
to regulate this gene has the potential to have a major impact on adoptive
immunotherapy treatment strategies.
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Chapter 2: Characterization of the Upstream Interferon Response
Region in Epithelial Tumor Cells

Introduction
Interferon gamma is a soluble cytokine that is secreted by a variety of cells including
CD4+ T cells and NK cells. It has the ability to activate macrophages and promotes
intracellular anti-viral activity by increasing the expression of both Class Ia and Ib
molecules. The mechanism of action of this cytokine has been shown to be mediated
primarily through tyrosine phosphorylation of STAT1α by JAK kinases upon binding to
the interferon gamma receptor. Phosphorylated STAT 1α then forms a homodimer,
which translocates to the nucleus and binds to the gamma activation site (GAS) of
various target genes. In the case of the HLA Class Ia genes, IFN-γ induces the
transcription of the interferon response factor-1 (IRF-1), which binds to the interferon
stimulated response element (ISRE) in the promoters of HLA-B or HLA-C, thereby
inducing transcription.
Similarly, the transcription of the HLA Class Ib gene, HLA-E, is also stimulated by IFN-γ
despite the lack of a functional ISRE in its promoter. Previous studies in our laboratory
show that HLA-E is induced via a variant STAT1α binding element, named the
Interferon Response Region (Gustafason et al 1996). The Upstream Interferon
Response Region (UIRR) is immediately adjacent to the IRR. We previously
demonstrated that the UIRR is bound by GATA1 in K562 stimulated cells and that the
activity of the UIRR confers a 5-fold enhanced response to IFN-γ above that of the IRR
(Barrett, Gustafson, Wang, Wang, & Ginder, 2004). GATA1 interacts with the HLA-E
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promoter in vivo, while GATA1 overexpression in the U937 cell line resulted in a 5-fold
increase in HLA-E induction. Since the expression of GATA transcription factors is celltype restricted, we investigated whether family members other than GATA1 could
support UIRR enhancer function.

Material and Methods

Cell Culture
The promonocytic cell line U937, erythroid leukemia K562, ovarian carcinoma OvCar 8,
ovarian carcinoma A2780, esophageal carcinoma Seg1, colon carcinoma HCT 116
were maintained in Roswell Park Memorial Institute 1640 medium (Invitrogen, Carlsbad,
CA) which was supplemented with 10% fetal bovine serum, 50 units/ml penicillin, and
50 ug/ml streptomycin (Invitrogen, Carlsbad, CA). The melanoma cell line, MeWo, was
maintained in MEM α medium supplemented with 10% fetal bovine serum, 50 units/ml
penicillin, and 50 ug/ml streptomycin (Invitrogen, Carlsbad, CA). Cells were induced
with interferon-gamma (RnD systems) at 200 units/ml or 300 units/ml for times
indicated. Doxycycline (Sigma-Aldrich, Saint Louis, MI) was used at 2 ug/ml and added
prior to interferon-gamma induction.
Quantitative reverse transcriptase PCR
Cytoplasmic RNA was isolated using the Trizol reagent system (Invitrogen, Carlsbad,
California). 1 ml or 0.5 ml of Trizol reagent was added to approximately 1 x10 6 (six well
dishes) or 3 x 105 (twelve well dishes), respectively, for ten minutes. The cells were
collected an added to a 1.5 ml microcentrifuge tube prior to the addition of 200
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microliters of chloroform. Cell lysate suspensions were shaken for thirty seconds and
allowed to settle for three minutes followed by centrifugation at 12000 x g at 4˚C. The
upper phase was removed to a fresh tube and 550 microliters of isopropanol was added
before a ten minute incubation at room temperature. The samples were then spun at
12000 x g at 4˚C for fifteen minutes. The supernatant was removed and the RNA pellet
was washed with 600 microliters of 70% ethanol/30% DEPC treated water. Samples
were spun at 7500 x g at 4˚C for five minutes. The supernatant was removed and
pellets were allowed to air dry for ten minutes. The pellet was resuspended in 100
microliters of 100% DEPC treated water. RNA was quantified by spectrophotometry.
Each RNA sample was then DNAse treated to remove any contaminated genomic DNA.
Specifically, 0.5 ul of Dnase I, 0.5 ul of Rnase Inhibin, plus water added to a total
volume of 20ul was added to 2 ug of RNA. The samples were incubated at 37˚C for
thirty minutes, and 75˚C for ten minutes to cause inactivation of the enzymes. Next,
cDNA was synthesized using the i-Script cDNA synthesis kit by Biorad. 500 ng of
DNAse I treated RNA was used for cDNA synthesis. The reaction mix consisted of 2 ul
of 5x iScript reaction mix, 0.5 ul of iScript reverse transcriptase, and nuclease free water
to ten microliters. The samples were then incubated as follows: 5 minutes at 25˚C, 30
minutes at 42˚C, 5 minutes at 85˚C, and 10 minutes at 4˚C. Each qPCR reaction was
performed using 20ng of cDNA. 12.5 ul of 2x Sybr Green Mix (Roche) and 7.5 ul of 1
nM primer mix containing forward and reverse primers (IDT) were used in each sample.
The primer sequences were as follows:
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Primers

Forward

Reverse

HLA-E

TTGCAAGGGCCTCTGAATCTGTCT

AGGAACACAGGTCAGTGTGAGGAA

STAT 1α

GTGCATCATGGGCTTCATCAGCAA

TAGGGTTCAACCGCATGGAAGTCA

Cyclophilin AGACAAGGTCCCAAAAGCAGA
A
CAT
ATCCCTGGGTGAGTTTCACCAGTT

TGTGAAGTCACCCTGACACAT

GFP

TGACCCTGAAGTTCAGCACCA

TGTAGTTGCCGTCGTCCTTGAAGA

GATA-1

AGACTTTGAAGACAGAGCGGCTGA

TTGGGAGAGGAATAGGCTGCTGAA

GATA-2

ATTGTCAGACGACAACCACCACCT

AGTGGCCTGTTAACATTGTGCAGC

GATA-3

TGCATCTGGGTAGCTGTAAGGCAT

GCATCAAACAACTGTGGCCAGTGA

GATA-4

TACATCAGCTTCCGGAACCACCAA

AATCCAGCATTGAGCAAAGGGCTC

GATA-5

AATGGCCGGTGATGTATGTCAGGA

AATCCAGGTTTCTGGCATTGCTGG

GATA-6

TCTACAGCAAGATGAACGGCCTCA

GTGTGACAGTTGGCACAGGACAAT

mGATA4

TCAAATTCCTGCTCGGACTTGGGA

GTTTGAACAACCCGGAACACCCAT

GGAAGCCATCACAAACGGCATGAT

Creation of stable cell lines
Knockdown of GATA-6
Previously the SKOV3TR cell line was created in the laboratory. Specifically, the
ovarian carcinoma SKOV3 was transfected with a plasmid that express the tet
Repressor protein. The cell line with the highest expression of recombinant protein was
named SKOV3TR and chosen to be transfected with the tetracycline inducible shRNA
vector, pSuperior.neo, which contained a 19 base pair sequence directed against
GATA6. The superior.neo vector contains a hybrid promoter with two binding sites for
the Tet Repressor molecules. The expression of GATA-6 shRNA is repressed in the
absence of tetracycline or doxycycline. Cells were selected with G418 (Invitrogen,
Carlsbad, CA) at 500 ug/ml until the cells began to proliferate at pre-selection levels.
The decrease of GATA-6 expression was confirmed using qPCR.
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Overexpression of GATA-4 and GATA-6
The cell lines MeWo and OvCar 8 were transfected with the expression vector
pCDNA/hGATA6, pCDNA/mGATA4, or a combination of both. The pCDNA1/mGATA-4
vector was a much appreciated gift from Dr. Jeff Molkentin. First the plasmids were
subcloned from the pCDNA1 vector into the pCDNA4 vector. The hGATA6 and
mGATA-4 cDNA fragments were isolated from the pCDNA1 plasmid by digestion with
Xho and BamH1.The resulting fragment was gel isolated and then ligated into the
pCDA4/TO vector that had also been digested with Xho and BamH1. The resulting
pcDNA4/hGATA6 and pcDNA4/mGATA4 plasmids were transfected both separately
and together into the MeWo and OvCar 8 cell lines. The cells were selected with
Zeocin at 150 ug/ml until the cells began to proliferate at pre-selection rates
(approximately four weeks). The cells were then pooled and will be referred to as
MeWo mGATA4, MeWo hGATA6, MeWo mGATA4/hGATA6, OvCar mGATA4, OvCar
hGATA6, and OvCar mGATA4/hGATA6. Overexpression of the GATA4 and GATA6
proteins were verified with western blot.
Preparation of CAT reporter gene constructs
The HLA-E 6.2 genomic clone, which was a gift from Dr. Harry Orr, was used to
generate the pECAT clone by sequentially subcloning Hind III-Pst I (-1700 to -174) and
PstI-AlwNI (-174 to +2) promoter fragments into the promotorless chloramphenicol
acetyltransferase (CAT) reporter gene (Promega, Madison, WI). The 5’ deletion
mutants pE386 and pE128 were generated by restriction digestion and subsequent religation of the plasmid. Further deletion mutants were generated by polymerase chain

26

reactions (PCR) using primers corresponding to -331 to -311, -281 to -262, and -231 to 210 of the HLA-E promoter, respectively, along with the addition of a Hind III site at the
5’ end of each primer. The primers were used in conjunction with an internal primer
corresponding to sequences in the CAT gene and pE386 plasmid as a template. The
PCR products were gel isolated, digested with Hind III and Pst I, gel isolated again, then
ligated into the pE386 plasmid that had been similarly digested and gel isolated
(Gustafson & Ginder, 1996).
The pCAT3/GFP construct was created by digesting a CMV driven GFP expression
plasmid with BamH1 and Xho I. The resulting fragment was gel isolated and ligated into
a pCAT3 plasmid that had been digested with Sal I and BamH1 and then gel isolated.
The resulting pCAT3/GFP plasmid was used to generate the CAT reporter gene
plasmids pE231/GFP, pE231mut/GFP, pE191/GFP and pE128/GFP. Specifically, the
UIRR-CAT, IRR-CAT, and Basal-CAT plasmids that were created previously were
digested with Kpn I and Nhe I. The resulting fragment was gel purified and ligated into
the pCAT3/GFP plasmid that was similarly digested and gel purified. The constructs
were sequenced by the dideoxy-chain termination method to verify endpoints and
mutated sequences. All restriction enzymes were purchased from New England
Biolabs (Beverly, MA).
Transient Transfection and CAT Reporter Gene Assays
Cells were plated the day before in 6 well dishes at a density of 3.0 x 10 5 using
Lipofectamine 2000 (Invitrogen). Briefly, 3 ug of CAT reporter plasmid plus 0.3 ug of
beta-galactosidase was diluted in 250 ul of serum free media. In a separate tube, 10 ul
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of Lipfectamine was added to 250 ul of serum free media. The mixture was incubated
at room temperature prior to addition to the DNA mixture. The diluted DNA plus the
diluted Lipofectamine was incubated for thirty minutes. 500 ul was added to each well.
The following day the appropriate wells were stimulated with 300 units of IFN-у/ml.
Transfected cells were removed from the 6 well dishes using trypsin (Invitrogen). The
cells were centrifuged at 8000xg at room temperature for 3 minutes. The media was
removed and the remaining cell pellet was washed with 800 ul of cold 1x PBS. The
cells were centrifuged at 8000xg at room temperature for 3 minutes. After removal of
the supernatant, the cell pellet was resuspended in 100 ul of 0.25M Tris-Cl and placed
in -80˚C for one hour. The cells were then lysed using a free-thaw method. Briefly, the
cells were placed at 37˚C for five minutes by vortexing. Next the cells were placed in a
100% ethanol ice bath for five minutes. The cells were then placed at 37˚C for five
minutes. These steps were repeated twice. Next the cells were centrifuged at 12000xg
for five minutes. The supernatant was removed to a fresh tube. 15 ul of sample was
combined with 1ul of 14C, 5 ul of n-Butyryl CoA, and 89 ul of 0.25M Tris-Cl. Each
sample was incubated for 90 minutes at 37˚C. The reaction was terminated by the
addition of 600 ul of xylenes. The samples were vigorously shaken then centrifuged at
12000xg for three minutes. 500 ul of the supernatant was removed to a fresh tube
followed by the addition of 100 ul of 0.25M Tris-Cl. After being vigorously shaken, the
samples were centrifuged at 12000xg for three minutes. 400 ul of the supernatant was
removed to a fresh tube followed by the addition of 100 ul of 0.25M Tris-Cl. The
samples were shaken and then centrifuged as above. 300 ul of the supernatant was
added to 6 milliliters of 4a20 scintillation fluid.
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CAT activity was normalized to internal beta-galactosidase activity. 15 ul of the cell
lysate was mixed with 135 ul of 0.25M Tris-Cl and 150 ul of 2x Assay Buffer (200 mM
Na2PO4, 2mM MgCl2, 100 mM β-mercaptoethanol, 1.33 mg/ml O-nitrophenyl-β-Dgalactopyranoside (ONPG) pH 7.3) the incubated thirty minutes at 37˚C. Reactions
were terminated with 700 ul of 1M Na2CO3 amd read at 420 nm on a UV
spectrophotometer. Units of β-galactosidase activity were determined using a standard
curve.
Transient Transfection and siRNA treatment
Cells were plated in a 12-well dish at a density of 2x104 cells per well. 40 picomoles of
siRNA was diluted in 100 ul of serum free media that was combined with 100 ul of
serum free media plus 5 ul of Lipofectamine. The mixture was incubated at room
temperature before addition of 200 ul to the appropriate well. After 72 hours of sirRNA
treatment, 200 units/ml of IFN-у was added to the appropriate wells. Cells were then
incubated for twenty-four hours at 37˚C and 5% CO2 before being harvested.
Western Blotting
Whole cell extracts were mixed with 2x SDS sample buffer [62.5 mM Tris pH 6.8, 30%
glycerol (v/v), 0.01% bromophenol blue (w/v)] then boiled for five minurtes at 100˚C.
Samples were loaded on a 4% stacking/10% resolving SDS Ready Gel from BioRad
(Hercules, CA) and run at 88 V at room temperature. The gel was first equilibrated in
100% methanol for twenty seconds and then in transfer buffer [(25mM Tris pH 8.3, 192
mM glycine, 20% methanol (v/v)] for ten minutes. Next the gel was transferred to a
PVDF membrane at 100 V and 4˚C for one hour. The membrane was blocked in 5%
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nonfat powdered Carnation milk (Nestle, Young America, MN) and 1x PBS-T [40 ml of
10x PBS-T (10 x PBS and 2.0 ml of Tween 20)] for one hour at room temperature with
shaking. Next the membrane was incubated in the appropriate primary antibody
(2ug/ml) in PBS-T plus 5% nonfat milk overnight at 4˚C with rocking. Unbound primary
antibody was removed by washing the blot for ten minutes with ten milliliters of 1x PBST followed by 3 five minute washes with 1x PBS-T. The membrane was then incubated
for one hour at room temperature with shaking in the appropriate secondary antibody
(1:4000) in PBS-T plus 5% nonfat milk. Unbound secondary antibody was removed by
one ten minute wash with PBS-T followed by 3 five minute washes. Protein was
visualized by enhanced chemiluminesence from BioRad (Hercules, CA).
Statistical Analysis
CAT reporter gene assay data was analyzed using Microsoft Excel to determine the
standard error of the mean. The standard deviation between samples was first
determined and then this value was divided by the square root of the number of
biological replicates. qPCR data was analyzed using the 2-∆CT method (Schmittgen
2008). Cyclophilin A was used as an endogenous control. Relative quantification was
determined as the ratio of the target gene to the housekeeping gene. Error was
reported as above. Significance was determined using the student’s t-test.
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Results
GATA Factor Screen and Analysis of UIRR Function
Previous investigation of the functional activity of the HLA-E promoter in the context of
the chloramphenicol acetyltransferase reporter gene assay demonstrated that the
interferon response region of the HLA-E promoter resides between -193 and -146
portion of the promoter. Inclusion of the promoter elements spanning to -386 of the
promoter resulted in a decrease in the transcriptional response to interferon gamma
treatment compared to inclusion up to -193 base pairs. In order to determine whether or
not this effect was cell type specific, CAT reporter constructs were also transfected into
the K562 erythroleukemia cell line (see Figure 4). When cells expressing the -386 and
-193 CAT plasmids expressed and the cells were stimulated with interferon gamma,
there was a five-fold increase in the transcriptional response with the -386 CAT plasmid
compared to the -193 CAT plasmid.
To further define the upstream element responsible increased CAT activity, we
constructed a series of 5’ deletions of the HLA-E promoter. It was determined that there
was an Upstream Interferon Response Region (UIRR) that could be localized to the 231 to the -194 portion of the HLA-E promoter. Analysis of potential transcription factor
binding sites using the MATInpsector 2.0 software showed that the potential candidates
that could be binding to the region were GATA binding transcription factor-1, Creb
Binding Protein, and My-T1 neurotransgenic factor. The Myt-1 transcription factor was
excluded from further analysis since it is only expressed in neural tissue. Mutagenesis
of the potential binding sites for GATA-1 and Creb binding protein indicated that
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changing the GATA binding site decreased the IFN-γ transcriptional activation of HLAE, whereas disrupting the CEBP binding site had no effect. Additionally, analysis of
protein expression showed expression of GATA-1 in the K562 cell line, which supports
the UIRR function, but not the in the U937 cell line, which does not support UIRR
function. This led to the hypothesis that GATA expression was necessary for the UIRR
response. Further investigation of the HLA-E transcriptional response in other tumor
cell lines seemed to uphold this theory. Specifically, the cell lines that were examined
were SKnMC, Tera-2, Hela, MeWo, Panc-1 (Figure 5). It was determined that those cell
lines that exhibited UIRR enhancer like function were also expressors of GATA binding
transcription factors. We decided to further investigate this phenomenon in cell lines that
were epithelial rather than hematopoietic in origin. This was of interest because the
expression of GATA transcription factors can be divided into two families. GATAs 1-3
are critical for hematopoietic cell development whereas GATAs 4-6 are necessary for
mesoendoderm development. Since we had previously demonstrated that GATA-1
could support UIRR function we decided to focus on the family members in the
“mesoendoderm” family. Based upon the known tissue expression of GATA4, GATA-5,
and GATA-6, the ovarian carcinoma A2780, the melanoma MeWo, the esophageal
carcinoma Seg1, the ovarian carcinoma OvCar8, and HCT 116 were screened for their
GATA expression via QPCR (Figures 6-11). Expression was normalized to expression
of the housekeeping gene Cyclophilin A. The ovarian carcinoma SKOV3, colon
carcinoma HCT 116, and esophageal carcinoma Seg1 were all determined to express
GATA6 mRNA.
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CAT Reporter Gene Constructs
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Figure 4. Diagram of CAT reporter gene constructs used in this study. Basal is the first
128 base pairs. The Interferon Response Region is located from -193 to -146 and the
UIRR is located from -231 to -194. GATA mutant plasmids have either the GA or the TA
core nucleotides of the GATA binding sequence mutated to a CC.
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Figure 5. Evaluation of UIRR Function in Various Tumor Cells Lines. (Courtesy of D. Barrett).
This preliminary work shows that tumor cells lines besides K562 can support UIRR
functionality. Each cell line was transfected with either the IRR or UIRR HLA-E promoter
driven plasmids for 3 hours prior to twenty-four stimulation with IFN-γ.
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Figure 6. Analysis of GATA-1 expression in various Tumor cells. RNA was isolated from the
indicated cells lines and screened for GATA-1 mRNA expression via qPCR. Expression of
GATA-1 was normalized to Cyclophilin A. qPCR was run for 40 cycles.

Endogenous GATA 2 Expression in Cell Lines
0.045
0.04
Relative Expression

0.035
0.03

Screen 1

0.025

Screen 2

0.02

Screen 3

0.015

Screen 4

0.01
0.005
0
K562 A2780 MCF7 Tera 2 Panc 1 U937 MeWo Seg 1

HCT OvCar SKOV3
116
8

Figure 7. Analysis of GATA-2 expression in various tumor cells. RNA was isolated from
the indicated cell line and screened for GATA-2 mRNA expression via qPCR. Expression
was normalized to Cyclophilin A. qPCR was run for 40 cycles.
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Figure 8. Analysis of GATA-3 expression in various tumor cell lines. RNA was isolated
from the cell lines above and screened for GATA-3 message via qPCR. qPCR was run for
40 cycles and GATA 3 expression was normalized to Cyclophilin A. MCF 7 was the only
cell line examined that was positive for GATA-3 expression.
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Figure 9. Analysis of GATA-4 expression in tumor cell lines. RNA was isolated from the
cell lines above and screened for GATA-4 message via qPCR. 40 cycles of qPCR was
performed and GATA-4 expression was normalized to Cyclophilin A. Tera2 and Panc1
were positive for GATA-4 expression.
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Figure 10. Evaluation of GATA-5 expression in various tumor cell lines. RNA was isolated
from the cell tumor cell lines indicated and analyzed for GATA-5 message. 40 cycles of qPCR
was performed and GATA-5 expression was normalized to Cyclophilin A. Panc 1 expressed
the highest amounts of GATA-5 mRNA transcript.
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Figure 11. Evaluation of GATA-6 expression in various tumor cell lines. RNA was isolated
from tumor cell lines above and analyzed for GATA-6 expression. 40 cycles of qPCR was
performed and GATA-6 expression was normalized to Cyclophilin A. Tera 2, HCT 116, SKOV3,
and Seg1 are positive for GATA-6 message.
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These cell lines were transfected with plasmids containing CAT reporter gene driven by
the HLA-E promoter. When expressed in HCT 116 cells, a 17.8 fold increase and a 47.9
fold increase in CAT activity versus a control CAT plasmid was observed from the IRR
plasmid and the UIRR plasmid, respectively (Figure 12). In Seg1 cells, a 7.2 fold
increase in CAT activity was measured from the IRR plasmid and a 28.7 fold increase
with the UIRR plasmid (Figure13). The SKOV3 cell line demonstrated a 20.6 fold
increase in CAT activity with the IRR plasmid compared to a 63.9 fold increase in CAT
activity with the UIRR plasmid (Figure 14). The ovarian carcinoma A2780 cell line was
shown to express low amounts of GATA factors 2 and 5(Figures 7, 10). When
transfected into A2780 cells, the IRR plasmid resulted in a 4.7 fold CAT activity and the
UIRR plasmid resulted in a 14.3 fold CAT activity (Figure 15). Therefore in each of
these cell lines there was a 2.4 fold to a 4.0 fold increase in CAT activity measured
from the UIRR above that of the IRR plasmid as wells as GATA transcription factor
expression.
The melanoma cell line, MeWo, and the ovarian carcinoma, OvCar 8, were also
screened for GATA transcription factor expression. The MeWo cell had no detectable
GATA family transcript levels as measured by qPCR (Figures 6-11), whereas the OvCar
8 cell line had very low expression of GATA-2 and GATA-6 transcripts (Figures 7,11).
When these cell lines were transfected with CAT reporter gene plasmids there was no
appreciable difference in CAT activity when comparing the IRR plasmid measurement
to the UIRR plasmid measurement. The IRR and UIRR reporters had a 6.8 fold and a
9.9 fold increase in CAT activity over control when expressed in MeWo cells (Figure
16), respectively. Similarly, the OvCar 8 cells exhibited a 9.7 fold CAT activity from the
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IRR plasmid and a 9.3 fold CAT activity from the UIRR plasmid (Figure 17). These
results suggest that other GATA family members have the ability to support UIRR
function and that these factors are necessary for the response via the UIRR.
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Figure 12. HCT 116 colon carcinoma cells display an increase in HLA-E promoter driven CAT
reporter gene activity via the UIRR. HCT 116 cells were plated overnight and then
transfected with CAT reporter gene plasmids as indicated in Figure 4. Cells were stimulated
with 200 units/ml of IFN-γ for 24 hours. Cells were then harvested using the freeze-thaw
method and the resulting supernatant was used to determine CAT activity. The fold
induction is the ratio of IFN stimulated cells compared to unstimulated cells that were
transfected with the same plasmid. # p=0.09; ## p=0.13, ### p=0.06
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Figure 13. Seg1 esophageal carcinoma cells exhibit UIRR functionality. Seg1 cells were
transfected with CAT reporter gene plasmids prior were plated overnight and then transfected
with CAT reporter gene plasmids as indicated in Figure 4. Cells were stimulated with 200 units/ml
of IFN-γ for 24 hours. Cells were then harvested using the freeze-thaw method and the resulting
supernatant was used to determine CAT activity. The fold induction is the ratio of IFN stimulated
cells compared to unstimulated cells that were transfected with the same plasmid. # p=0.08; ##
p=0.09, ### p=0.06
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Figure 14. SKOV3 ovarian carcinoma cells exhibit UIRR functionality. SKOV3 cells were
transfected with CAT reporter gene plasmids prior were plated overnight and then
transfected with CAT reporter gene plasmids as indicated in Figure 4. Cells were stimulated
with 200 units/ml of IFN-γ for 24 hours. Cells were then harvested using the freeze-thaw
method and the resulting supernatant was used to determine CAT activity. The fold
induction is the ratio of IFN stimulated cells compared to unstimulated cells that were
transfected with the same plasmid. # p=0.21; ## p= 0.21, ###p= 0.13
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Figure 15. A2780 ovarian carcinoma cells exhibit UIRR functionality. A2780 cells were
transfected with CAT reporter gene plasmids prior were plated overnight and then transfected
with CAT reporter gene plasmids as indicated in Figure 4. Cells were stimulated with 200 units/ml
of IFN-γ for 24 hours. Cells were then harvested using the freeze-thaw method and the resulting
supernatant was used to determine CAT activity. The fold induction is the ratio of IFN stimulated
cells compared to unstimulated cells that were transfected with the same plasmid. * p= 0.0007;
** p= 0.007, *** p= 0.002
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Figure 16. MeWo cells do not support UIRR function. MeWo cells were transfected with
CAT reporter gene plasmids prior were plated overnight and then transfected with CAT
reporter gene plasmids as indicated in Figure 4. Cells were stimulated with 200 units/ml of
IFN-γ for 24 hours. Cells were then harvested using the freeze-thaw method and the
resulting supernatant was used to determine CAT activity. The fold induction is the ratio of
IFN stimulated cells compared to unstimulated cells that were transfected with the same
plasmid. # p= 0.06; ## p= 0.48; p= 0.12
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Figure 17. OvCar 8 cells do not support UIRR function. OvCar 8cells were transfected with CAT
reporter gene plasmids prior were plated overnight and then transfected with CAT reporter
gene plasmids as indicated in Figure 4. Cells were stimulated with 200 units/ml of IFN-γ for 24
hours. Cells were then harvested using the freeze-thaw method and the resulting supernatant
was used to determine CAT activity. The fold induction is the ratio of IFN stimulated cells
compared to unstimulated cells that were transfected with the same plasmid. # p= 0.04; ## p=
0.95; ### p=0.1
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Mutation of the GATA binding site
The A2780 and the SKOV3 cell lines which have been shown to express GATA-2 and
GATA-5 (A2780) or GATA-6 (SKOV3) were transfected with plasmids in which the
GATA binding site was mutated. Specifically, the GA nucleotides or TA nucleotides
were mutated to a CC. In the case of A2780, the mutated binding site resulted in a
reduction of CAT activity to a 2.9 fold increase in CAT activity when the GA nucleotides
were altered or a 3.0 fold increase in CAT activity when the TA nucleotides were
substituted. This amount of CAT activity was similar to the CAT activity when the IRR
plasmid was transfected alone. Thus mutating the GATA binding site caused a 4 fold
decrease in CAT activity when compared to wild type UIRR (Figure 18). When the
SKOV3 cell line was transfected with CAT reporter plasmids containing GATA binding
site mutations there was a significant decrease in CAT activity. Specifically mutating the
GA binding site caused an eight fold decrease whereas mutating the TA portion caused
a fourteen fold decrease in interferon induced CAT reporter gene activity (Figure 19).
This was particularly interesting since there was only a 3 fold increase in CAT reporter
gene activity when comparing interferon induction between the IRR plasmid and the
UIRR plasmid. Mutation of the GATA element should prevent binding of the GATA
transcription family members. Binding partners may exist that facilitate protein-protein
interactions between the GATA factor on the UIRR element and the STAT homodimer
on the IRR element. Perhaps the lack of GATA transcription factor binding prevents
interaction with the STAT molecules and therefore causes an even lower interferon
induction than with the IRR alone. This large decrease could also indicate the need for
other binding partners in the A2780 cell line as compared to the SKOV3 cell line.
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Another possibility is that the cell lines express the same binding partners but that these
factors do not have the ability to interact with GATA-2 or GATA-5. Note that SKOV3
expresses GATA-6.

**
*

Figure 18. Mutation of the GATA binding element eliminates the ability of A2780 cells to
support UIRR function. A2780 cells were transfect with CAT reporter gene plasmids. Cells
were stimulated with 200 units/ml of IFN-γ for 24 hours. Cells were then harvested using the
freeze-thaw method and the resulting supernatant was used to determine CAT activity. The
fold induction is the ratio of IFN stimulated cells compared to unstimulated cells that were
transfected with the same plasmid. Expression was normalized to β-gal. * p= 0.004; ** p=
0.004
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Figure 19. Mutation of the GATA binding element eliminates the ability of SKOV3 cells to
support UIRR function. SKOV3 cells were transfect with CAT reporter gene plasmids as
indicated in Figure 4. Cells were stimulated with 200 units/ml of IFN-γ for 24 hours. Cells
were then harvested using the freeze-thaw method and the resulting supernatant was used
to determine CAT activity. The fold induction is the ratio of IFN stimulated cells compared
to unstimulated cells that were transfected with the same plasmid. Expression normalized
to β-gal. # p= 0.15; ## p= 0.16
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Knockdown of GATA Transcription Factor Expression
As a complement to the mutation studies we ablated the expression of GATA
expression to determine the effect on transient and endogenous HLA-E transcription.
The Seg 1 cell line was previously shown to express GATA-6. This cell line was
transfected with a GATA-6 specific siRNA targeting. There was an 80% knockdown of
the GATA-6 message (Figure 20) which resulted in a 40% reduction in the induction of
HLA-E gene transcription when compared to wild type (Figure 21). STAT 1 alpha
siRNA, which is required for HLA-E induction, was knocked down with a specific siRNA
as a positive control. The expression of STAT 1 alpha was decreased by 55% and
resulted in approximately a 44% reduction in HLA-E transcription (Figure 20).
The colon carcinoma, HCT 116, was shown to express GATA-6 as well. The expression
of GATA-6 was decreased by 60% (Figure 22) while the expression of STAT 1 alpha
was decreased by 40% (Figure 22). The decrease of each transcription factor resulted
in a 32% decrease in the expression of endogenous HLA-E induction (GATA-6) or no
appreciable decrease (STAT1α), respectively (Figure 23). The lack of decrease in HLAE induction is most likely due to an inadequate decrease in STAT expression.
The effect of GATA-6 gene targeting on HLA-E transcription was also examined in the
SKOV3 carcinoma cell line. The cells were transfected with a pSuperior.neo vector
which contained Tet Repressor binding sites in its promoter which therefore renders the
expression of GATA-6 shRNA to be tetracycline regulated. SKOV3TR/GATA6 cells
were selected with 500 mg/ml of tetracycline for approximately three weeks. Single cell
clones were then selected and expanded. The ability to knockdown the expression of
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GATA-6 was determined using qPCR. Clones #1, #34, #49, #58 and #81 were treated
with 2 ug/ml of doxycyline for 72 hours prior to quantitation of GATA-6 mRNA. There
was a 46.7% decrease in GATA-6 message in clone #1 when treated with doxycyline,
an 81.6% decrease in clone #34, a 63.3% decrease in clone #49, and a 79.3%
decrease in clone #81 (Figure 24). Some of the clones were also transfected with CAT
reporter gene constructs to determine the functional effects of GATA-6 knockdown on
the HLA-E promoter. For the clones #1, #8, #32, and #58, a 3 fold decrease in CAT
reporter gene activity was detected only when clone #1 was treated with doxycycline for
72 hours followed by stimulation with interferon gamma for 24 hours (Figure 25). In
summary, the knockdown of GATA-6 in the cell lines Seg 1, HCT 116, and SKOV3
resulted in a decrease in GATA-6 expression. The decrease in endogenous HLA-E
induction was determined to be 40% in Seg 1 cells and 30% in HCT 116 cells. Analysis
of HLA-E induction in the SKOV3 GATA-6 knockdown clones compared to their wildtype counterparts did not demonstrate a difference in the induction of HLA-E
transcription (Figure 26- 29).
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Figure 20. Gene targeting causes a decrease in GATA-6 and STAT 1α expression in Seg esophageal
carcinoma cells. Seg1 cells were plated overnight and then transfected with siRNA specific for GATA-6, STAT
1α, or scramble control. After 72 hours of exposure to siRNA , the cells were stimulated with 200 units/ml of
IFN-γ. Total RNA was obtained from cells and the expression of GATA-6 (A) and STAT 1 α was determined.
Target gene expression was normalized to human Cyclophilin A.
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Figure 21. Effect of gene targeting on Endogenous HLA-E Expression in Seg 1 esophageal
carcinoma cells. Cells were treated as described in Figure 20. Expression was normalized to
human Cyclophilin A. The amount of induction was compared to scramble control. *
p=0.01; ** p= 0.03
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Figure 22. Gene targeting causes a decrease in GATA-6 and STAT 1α expression in HCT116 colon
carcinoma cells. HCT116 cells were plated overnight and then transfected with siRNA specific for
GATA-6, STAT 1α, or scramble control. After 72 hours of exposure to siRNA , the cells were stimulated
with 200 units/ml of IFN-γ. Total RNA was obtained from cells and the expression of GATA-6 (A) and
STAT 1 α was determined. Target gene expression was normalized to human Cyclophilin A.
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Figure 23. Effect of gene targeting on HLA-E expression in HCT 116 colon carcinoma
cells. Cells were treated as described in Figure 22. Expression was normalized to human
Cyclophilin A. The amount of induction was compared to scramble control. #p= 0.06
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Figure 24. Analysis of GATA-6 expression in SKOV3 knockdown clones. Clones were treated
for 72 hours with 2ug/ml of doxycyline prior to RNA isolation. qPCR was used to determine
GATA-6 expression. Expression was normalized to Cyclophilin A.
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Figure 25. CAT Activity in SKOV3 Knockdown clones. Each clone was treated with 2ug/ml
of doxycycline prior to transfection with CAT reporter gene plasmids. Six hours later cells
were stimulated with IFN-γ. Cells were stimulated for 24 hrs and then harvested using the
freeze-thaw method and the resulting supernatant was used to determine CAT activity.
The fold induction is the ratio of IFN stimulated cells compared to unstimulated cells that
were transfected with the same plasmid.
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CAT activity was determined 24 hours later.
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Figure 26. Analysis of Endogenous HLA-E induction in SKOV3 GATA-6 knockdown clone
#1. Clones were treated for 72 hours with 2ug/ml of doxycycline prior to stimulation with
IFN-γ for an additional 24 hr. Total RNA was isolated and qPCR was run for 40 cycles.
Expression was normalized to Cyclophilin A.
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Figure 27. Analysis of Endogenous HLA-E induction in SKOV3 GATA-6 knockdown clone
#58. Clones were treated for 72 hours with 2ug/ml of doxycycline prior to stimulation with
IFN-γ for an additional 24 hr. Total RNA was isolated and qPCR was run for 40 cycles.
Expression was normalized to Cyclophilin A.
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Figure 28. Analysis of Endogenous HLA-E induction in SKOV3 GATA-6 knockdown clone #49.
Clones were treated for 72 hours with 2ug/ml of doxycycline prior to stimulation with IFN-γ for
an additional 24 hr. Total RNA was isolated and qPCR was run for 40 cycles. Expression was
normalized to Cyclophilin A.
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Figure 29. Analysis of Endogenous HLA-E induction in SKOV3 GATA-6 knockdown clone
#81. Clones were treated for 72 hours with 2ug/ml of doxycycline prior to stimulation with
IFN-γ for an additional 24 hr. Total RNA was isolated and qPCR was run for 40 cycles.
Expression was normalized to Cyclophilin A.
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Overexpression of GATA Factors
The parallel gain of function experiment was also performed in the GATA-6 null cell
lines OvCar 8 and MeWo. These cell lines were transfected with pCDNA4/TO
overexpression plasmids which contained cDNA for mGATA4 or hGATA6. The
transfected cells were selected with 100 ug/ml of Zeocin and then pooled. Each cell line
was tested for GATA factor expression via qPCR and Western Blot analysis.
The OvCar 8 cell line was shown to express very low levels of GATA-2 and GATA-6
message, but was incapable of supporting UIRR function. Therefore we wanted to
determine if UIRR functionality could be achieved by ectopically expressing GATA-4
and/or GATA-6 in the OvCar 8 cell line. The resulting overexpression pools were
designated OvCar M4, OvCar H6 or OvCar M4H6 and were examined for GATA-4 and
GATA-6 expression via qPCR. The OvCar M4 pools and the OvCarM4H6 pools
showed an 8 fold and 14 fold increase in GATA4 expression compared to vector alone
(Figure 31 A). Additionally, expression of GATA6 transcript was 4 fold higher in the
OvCar H6 pools compared to vector alone (Figure 32 A). Examination of protein
expression showed no discernable difference in GATA4 expression between the OvCar
vector, OvCar M4 and OvCar M4H6 cell lines (Figure 33A). In fact, GATA-4 expression
was detected in all three overexpression pools despite the lack of detectable GATA4
transcript in the OvCar vector pool or wild-type OvCar 8. Similarly GATA-6 protein was
detected in the OvCar vector pool. However there was a clear increase in GATA-6
protein expression in both the OvCar H6 and OvCar M4H6 overexpression pools
(Figure 33B).
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Each overexpression pool was transfected with a dual CAT reporter gene plasmid and
then CAT gene expression was determined by qPCR. Gene expression was
normalized to the Cyclophilin A housekeeping gene and transfection efficiency was
determined by dividing the expression of the CAT gene to the expression of the GFP
gene. There was a 3.8 fold increase in CAT gene expression read from the UIRR
plasmid above that of the IRR plasmid detected in the OvCar M4 cell line (Figure 31C).
Mutation of the GATA binding site resulted in a reciprocal decrease in CAT gene
expression. We were unable to detect a difference in CAT gene activity in the OvCar
H6 or OvCar M4H6 cell lines (Figures 32C and 33C). Finally we analyzed the effect of
GATA-4 and GATA-6 overexpression on endogenous HLA-E gene induction. We did
not observe a difference in HLA-E induction when comparing the overexpression pools
to the vector control (Figure 34).
The melanoma cell line MeWo was also transfected with overexpression plasmids for
GATA-4, GATA-6, and GATA-4 plus GATA-6. After a three week selection period, the
cells were pooled and analyzed for mRNA transcript levels and protein expression. The
expression of GATA-4 and GATA-6 was evaluated via qPCR. Analysis of GATA-4 gene
expression in the MeWo vector, MeWo H6, and the MeWo M4H6 cell lines revealed a
40 fold increase in GATA-4 expression in the MeWo M4 cell line above that of the
vector control (Figure 35A). Similarly, GATA6 transcript levels were similar 4 fold higher
and 30 fold higher in the MeWo H6 and MeWo M4H6 cell lines, respectively (Figure
36A). We also determined that GATA-4 protein levels were 2 fold higher in the MeWo
M4 and MeWo M4H6 cell lines (Figure 37A). GATA-6 protein levels were also
approximately two fold higher in the MeWo H6 and MeWo M4H6 cell lines (Figure 38B).
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The MeWo overexpression pools were transfected with CAT reporter gene plasmids,
stimulated with 200 units/ml of IFN-γ, and the analyzed for CAT gene expression via
qPCR. MeWo H6 cells showed a 3.5 fold induction in CAT gene expression when cells
were transfected with the IRR plasmid and a 3.0 fold increase in CAT gene expression
with the UIRR plasmid (Figure 36C). However, we were unable to detect IFN induction
in the either the MeWo M4 or MeWo M4H6 cells (Figure 35C and Figure 37C). The
endogenous expression of HLA-E was also examined in the MeWo overexpression
pools. The MeWo M4H6 cell line exhibited a 3 fold higher induction than MeWo vector,
but surprisingly the MeWo M4 cell line showed no enhancement in HLA-E transcription
when compared to the MeWo vector control (Figure 38).
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Figure 30. Schematic of the HLA-E promoter driven dual reporter gene. Overexpression pools
were transfected with plasmids designated as Basal, IRR, UIRR, or MUT. CAT expression was
normalized to GFP expression to determine transfection efficiency.
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Figure 31. Evaluation of GATA4 Overexpression in OvCar ovarian cancer cells. A. Total RNA was
harvested from OvCar 8 cells transfected with vector alone, GATA 4 or GATA4 and GATA6. Expression was
normalized to human Cyclophilin A. B. GATA 4 protein expression was analyzed by western blot. C. HLAE promoter driven gene expression was analyzed as described earlier. # p= 0.20 (Comparison of UIRR
induction to IRR induction).
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Figure 32. Evaluation of GATA6 Overexpression in OvCar ovarian cancer cells. A. Total RNA was
harvested from OvCar 8 cells transfected with vector alone, GATA 6 or GATA4 and GATA6. Expression
was normalized to human Cyclophilin A. B. GATA 6 protein expression was analyzed by western blot. C.
HLA-E promoter driven gene expression was analyzed as described earlier.
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Figure 33. Evaluation of GATA4 and GATA6 Overexpression in OvCar ovarian cancer cells. A. GATA-4 protein
expression was examined in OvCar M4H6 pools by western blot. B. GATA-6 protein expression was analyzed
in OvCar M4H6 cells by western blot. C. HLA-E promoter driven gene expression was analyzed as described
earlier.
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Figure 34. Analysis of HLA-E induction in OvCar Overexpression Pools. Cells were
treated for 24 hours with 200 units/ml of IFN-γ prior to RNA isolation. Expression was
normalized to human Cyclophilin A.
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Figure 35. Evaluation of GATA4 Overexpression in MeWo melanoma cells. A. Total RNA was harvested
from MeWo cells transfected with vector alone, GATA 4 or GATA4 and GATA6. Expression was
normalized to human Cylophilin A. B. GATA 4 protein expression was analyzed by western blot. C. HLAE promoter driven gene expression was analyzed as described earlier.
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Figure 36. Evaluation of GATA6 Overexpression in MeWo melanoma cells. A. Total RNA was harvested
from OvCar 8 cells transfected with vector alone, GATA 4 or GATA4 and GATA6. Expression was normalized
to human Cylophilin A. B. GATA 6 protein expression was analyzed by western blot. C. HLA-E promoter
driven gene expression was analyzed as described earlier.

66

Nonspecific
GATA 4

GATA 6

Actin
Actin

C

Figure 37. Evaluation of GATA4 and GATA6 Overexpression in MeWo melanoma cells. A. GATA-4
protein expression was examined in MeWo M4H6 pools by western blot. B. GATA-6 protein
expression was analyzed in MeWo M4H6 cells by western blot. C. HLA-E promoter driven gene
expression was analyzed as described earlier.
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Figure 38. Analysis of HLA-E induction in MeWo Overexpression Pools. Cells were treated for
24 hours with 200 units/ml of IFN-γ prior to RNA isolation. Expression was normalized to human
Cyclophilin A. MeWo M4H6 exhibited an increased response to IFN-γ compared to vector
control. # p=0.26
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Discussion
In this study we have shown that GATA transcription family members other than GATA1 can promote enhancement of HLA-E gene expression in response to IFN-γ. We
evaluated the ability of various tumor cell lines to support UIRR function and screened
these cell lines for GATA gene expression via qPCR. We determined that the HCT116,
Seg1, SKOV3 and A2780 cell lines supported a 2.4 to 3.0 fold increase in CAT reporter
gene activity via the UIRR plasmid above that of the IRR plasmid alone. Some of our
strongest supporting data is the GATA binding site mutation studies. We demonstrated
that alteration of either the GA or TA portion causes a decrease in CAT reporter gene
activity in the SKOV3 and A2780 cell lines. Furthermore, we targeted GATA-6
expression in order to ascertain the effect on HLA-E promoter driven CAT reporter gene
activity and endogenous HLA-E expression. We used siRNA gene knockdown to
decrease the expression of GATA6 in the Seg1 and HCT 116 cell lines. Although we
obtained a similar level of transfection efficiency in both cell lines as visualized with an
Alexa fluorophore labeled negative siRNA control (data not shown), we were able to
achieve greater gene knockdown in the Seg1 cell line. We are currently developing a
GATA-6 miRNA construct that will be packaged into a lentivirus vector in hopes that we
will be able to achieve a higher level of GATA6 knockdown and therefore observe a
greater effect on HLA-E induction.

We also created a stable, tetracycline inducible GATA-6 knockdown cell line,
SKOV3TR/GATA6. We selected single cell clones to expand for future studies. One of
the benefits of a tetracycline inducible cell line is that the untreated cells are an ideal
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negative control. One of the difficulties we experienced with this technology is variable
knockdown in the same clones between treatment periods. We demonstrated the
decrease of GATA-6 gene expression from a range of 46% to 80% but saw no effect on
endogenous HLA-E expression in any of the clones. This suggests that a higher
amount of knockdown is needed to see an effect on HLA-E induction. It also raises the
question of compensation by another GATA family member. However, this is unlikely
since a previous GATA factor protein screen showed that only GATA-6 is expressed in
the SKOV3 cell line. Furthermore, there have been no studies that implicate GATA-6 as
a negative regulator of the other GATA family members.

We demonstrated the ability to overexpress GATA-4 and GATA-6 proteins in the OvCar
8 and MeWo cell lines. We saw an increase in GATA4 transcript levels in the OvCar
M4, OvCar M4H6 and the MeWo M4 cell lines. We also saw an increase in GATA-4
protein expression however the total amount of protein was low. There was also a
slightly nonspecific band that ran slight higher than GATA-4. This raises the question if
there was recognition of another GATA family member or an antigenically similar 50
kDa protein by the GATA-4 antibody. If so, there may have been an increase in GATA4 protein levels that is masked by the expression of the other protein. Despite the
detection of increased GATA6 protein levels in the OvCar H6 and the OvCar M4H6 cell
lines, we saw no effect on CAT reporter gene activity in these cells.

However, it is important to point out that no clear conclusion of CAT gene expression
could be made due to subsequent difficulties in visualizing CAT gene induction.
Overexpression pools were transfected with 3 ug of CAT reporter gene plasmids prior to
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IFN-γ stimulation. However the detection of CAT gene expression in the unstimulated
cells was observed at 14-16 cycles of qPCR. This rapid detection suggests very high
levels of gene expression and further illustrated the need for transfection of lower
amounts of reporter gene plasmid. We repeated our studies using 1ug of plasmid but
obtained similar results (data not shown). It is important to note that there were no
difficulties in obtaining induction in our initial studies in the OvCar M4 cell line. Future
attempts will be made to examine the effect of GATA overexpression on CAT reporter
gene expression. We plan to further decrease the amount of DNA transfected into cells.
Alternatively, if these experiments prove unsuccessful, we will switch back to evaluating
CAT protein activity using our single reporter gene plasmids.

We also demonstrated the ability to increase GATA-4 protein expression in the MeWo
M4 and MeWo M4H6 cell lines as well as GATA-6 protein expression in the MeWo H6
and MeWo M4H6 cell lines. Although there was an obvious increase in GATA6 protein
levels the absolute amount of protein detected in both cell lines was low. We observed
a 3 fold increase of endogenous HLA-E induction in the MeWo M4H6 cell line. The
protein data suggests that this effect may be attributed more to GATA-4 overexpression
than GATA-6.

GATA transcription family members were named based upon the ability to recognize
and bind to WGATAR sequences in the promoters of target genes. There are several
examples of different GATA family members regulating the expression of the same
gene. For example, both GATA-4 and GATA-5 can regulate the expression of the Atrial
Natriuretic Factor 1 in cardiac cells (Takaya 2008). However there are examples where
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one GATA factor regulates gene expression, while another does not. For example, only
GATA-6 regulates the expression of the Indian hedgehog gene (Ihh) which is required
for proper gut development (Haveri 2008). Our present studies indicate that GATA-4,
GATA-5, and GATA-6 can regulate HLA-E gene expression. Previous studies indicate
that GATA1 binds to the HLA-E promoter in vivo. Although we have observed GATA-4
and GATA-6 interaction with radiolabeled UIRR sequences in vitro, it still remains to be
seen if GATA-4 or GATA-6 can bind to the HLA-E promoter in vivo.
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Chapter 3: Identification of Putative Components of the Interferon
Response Region Activation Complex

Introduction
Interferon gamma is a soluble cytokine that is secreted by a variety of cells including
CD8+ T cells and NK cells. It has the ability to activate macrophages and promotes
intracellular viral activity by increasing the expression of both Class Ia and Ib molecules.
The mechanism of action of this cytokine has been shown to be mediated primarily
through tyrosine phosphorylation of STAT1α by JAK kinases upon binding to the
interferon gamma receptor. Phosphorylated STAT 1α then forms a homodimer, which
translocates to the nucleus and binds to the gamma activation site (GAS) of various
target genes. In the case of the HLA Class Ia genes, IFN-γ induces the transcription of
the interferon response factor-1 (IRF-1), which binds to the interferon stimulated
response element (ISRE) in the promoters of HLA-B or HLA-C, thereby inducing
transcription.
Similarly, the transcription of the HLA Class Ib gene, HLA-E, is also stimulated by IFN-γ
despite the lack of a functional ISRE in its promoter. Previous studies in our laboratory
show that HLA-E is induced via a variant STAT1α binding element, named the
Interferon Response Region (Gustafason et al 1996). This binding element consists of
two half sites which are similar to but are not consensus matches of the GAS and ISRE,
respectively. Experiments using the drugs Distamycin A and Netropsin, which interact
with the minor groove, were able to disrupt the formation of the IRR-AC, suggesting that
a minor groove binding protein was present in the complex.
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High mobility group A (HMGA1) is a nuclear, non-histone chromosomal protein that
binds to AT rich sequences in the minor groove binding protein region. The four
members of the HMG family, HMGA1a, HMGA1b, HMGA1c, and HMGA2, have been
shown to play a role in transcriptional activation and modulation of chromatin structure
(Chau 2005). HMGA1a, HMGA1b, and HMGA1c are splice variants that are transcribed
from the same gene. All members of this family contain a Pro-Arg-Gly-Pro AT hook
domain (Reeves 2001). The binding of these factors to the minor groove results in
bending of the DNA molecule and permits interactions of transcription factors on
adjacent parts of the promoter, which is illustrated in IFN-γ gene expression (Chau
2009). Additionally, overexpression of HMGA1 has been linked to metastatic
progression and poor prognosis in pancreatic cancer (Cai 2009).
The polypyrimidine binding protein-associated factor (PSF) is another potential
candidate of the Interferon Response Region Activation Complex. PSF, which also
contains an AT-hook domain, has been shown to bind DNA and to function in
coordination with known transcription factors, including SP-1 and Sin3A (Mathur,
Tucker, & Samuels, 2001; Urban & Bodenburg, 2002). Furthermore, PSF was identified
by mass spectroscopy of the purified complex. The previous findings as well as the
inherent characteristics of proteins suggest that they could play a role in transactivation
of the HLA-E gene. However, further studies are needed in order to definitively show
what proteins bind to the interferon response region of the HLA-E promoter.
The paradigm with interferon stimulated gene expression has always been that IFN-α/β
induces ISGF3 complex formation, while IFN-γ induces GAF complex formation. The
Interferon Regulatory Factor (IRF) Family plays in the cellular response to viral
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infections. IRF9, or p48, was identified as a component of the ISGF3 complex that
binds to the Interferon Stimulated Response Element in response to IFN-α. However,
Blussyen et al showed that the ISRE of the ISG15 gene could be activated by STAT1α
homodimer/IRF9 complex when interferon gamma stimulation was preceded by IFNstimulation (1996). Recent studies show that other STAT containing complexes can be
activated in response to IFN-γ signaling and bind to the GAS of target genes, such as a
STAT 3 homodimer or a STAT1:STAT3 heterodimer (Wesoly 2007). The Interferon
Response Region consists of an ISRE-like half site and a GAS-like half site. Based
upon these studies, we decided to investigate the role of IRF-9 in HLA-E induction.
There is also the possibility of a bridging factor that interacts with the STAT 1α molecule
that binds to the Interferon Response Region and the GATA factor that binds to the
Upstream Interferon Response Region. This hypothesis was developed based upon
the observation that the IRR is not a consensus STAT binding site and the UIRR is not
a consensus binding sites GATA. Since p300/CBP has been shown to interact with
STAT1 and some members of the GATA transcription family, we decided to test if p300
activity was required for the full induction of the HLA-E gene.
The p300/CREB-binding protein (CBP) family functions as transcriptional coactivators
that promote an active chromatin state by acetylating histones and allowing RNA
polymerase II access to gene promoters (Chan 2001, Giordano 1999, Zhang 1996).
The p300 protein was discovered due to its ability to interact with Adenovirus E1a
oncoprotein (Whyte 1989). Likewise, the CBP protein was identified based upon its
interaction with the cAMP responsive element binding protein (Chrivia 1993). CBP and
p300 share sequence homology in five separate protein domains: the three cysteine75

histidine rich regions, the KIX domain (binding site for CREB), the bromodomain, the
HAT domain and the steroid receptor coactivator 1 interaction (SID) domain (Kalkhoven
2004). These similar domains suggest the ability to interact with the same proteins and
thus a similarity in function. For example, both proteins interact with the general
transcription factors TFIIB, TBP, and RNA polymerase II, RNA helicase A (Blobel 2002
and Giordano 1999).
The association of p300 with gene specific transcription factors has been shown to
enhance their transactivation capabilities. For example, p300 was shown to interact
with STAT 1 at both the N-terminus and the C-terminus in response to IFN-γ (Zhang
1996). Additionally, p300 has been shown to interact with GATA-1, GATA-4, GATA-5,
and GATA-6 (Boyes 1998, Kakita 1999, Wada 2000, Takaya 2008, Chen 2009).
Miyomato et al showed that overexpression of p300 in transgenic mice resulted in
acetylation of GATA-4 and myocardial cell hypertrophy, while a mutant lacking p300
histone acetyltransferase activity could not support either of these activities (2006).
Takaya et al further investigated the interaction between GATA-4 and p300 via mutation
of target lysine residues in the C-terminal motif and discovered that GATA-4’s ability to
transactivate the atrial natriuretic factor 1 (ANF-1) and the endothelial 1 promoters was
reduced (2008). Additionally, p300 has been shown to associate with GATA-6 to help
promote activation of the smooth muscle-myosin heavy chain gene (Wada 2000).
Furthermore, Adenovirus E1a transfection into vascular smooth muscle cells or cardiac
muscle cells downregulated the expression of the smooth muscle myosin heavy chain
gene and the atrial natriuretic factor gene (Wada 2000 and Kakita 1999).
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In order to determine the role of p300 in HLA-E gene activation, we decided to cotransfect wild type and mutant Adenovirus E1a with CAT reporter gene plasmids
containing the IRR or the UIRR+IRR. It was determined that both wild-type E1a and a
mutant that was only able to bind p300/CBP caused a 6 fold decrease in interferon
induction via the UIRR in K562 cells. We decided to evaluate this interaction further by
siRNA targeting of p300 expression in the SKOV3 cell line.

Material and Methods
Cell Culture
The ovarian carcinoma, SKOV3 was maintained in Roswell Park Memorial Institute
1640 medium (Invitrogen, Carlsbad, CA) which was supplemented with 10% fetal
bovine serum, 50 units/ml penicillin, and 50 ug/ml streptomycin (Invitrogen, Carlsbad,
CA). Cells were induced with interferon-gamma (RnD systems) at 200 units/ml for times
indicated.
Transient Transfection and siRNA treatment
Cells were plated in a 12-well dish at a density of 2x104 cells per well. 40 picomoles of
siRNA were diluted in 100 ul of serum free media that was combined with 100 ul of
serum free media plus 5 ul of Lipofectamine. The mixture was incubated at room
temperature before addition of 200 ul to the appropriate well. After 72 hours of siRNA
treatment, 200 units/ml of IFN-у was added to the appropriate wells. Cells were then
incubated for twenty-four hours at 37˚C and 5% CO2 before being harvested.
qRT-PCR
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Cytoplasmic RNA was isolated using the Trizol reagent system (Invitrogen, Carlsbad,
California). 1 ml or 0.5 ml of Trizol reagent was added to approximately 1 x106 (six well
dishes) or 3 x 105 (twelve well dishes), respectively, for ten minutes. The cells were
collected an added to a 1.5 ml microcentrifuge tube prior to the addition of 200
microliters of chloroform. Cell lysate suspensions were shaken for thirty seconds and
allowed to settle for three minutes followed by centrifugation at 12000 x g at 4˚C. The
upper phase was removed to a fresh tube and 550 microliters of isopropanol was added
before ten minute incubation at room temperature. The samples were then spun at
12000 x g at 4˚C for fifteen minutes. The supernatant was removed and the RNA pellet
was washed with 600 microliters of 70% ethanol/30% DEPC treated water. Samples
were spun at 7500 x g at 4˚C for five minutes. The supernatant was removed and
pellets were allowed to air dry for ten minutes. The pellet was resuspended in 100
microliters of 100% DEPC treated water. RNA was quantified by spectrophotometry.
Each RNA sample was then DNAse treated to remove any contaminated genomic DNA.
Specifically, 0.5 ul of DNase I, 0.5 ul of RNase Inhibin, plus water added to a total
volume of 20ul was added to 2 ug of RNA. The samples were incubated at 37˚C for
thirty minutes, and 75˚C for ten minutes to cause inactivation of the enzymes. Next,
cDNA was synthesized using the i-Script cDNA synthesis kit by Biorad. 500 ng of
DNAse I treated RNA was used for cDNA synthesis. The reaction mix consisted of 2 ul
of 5x iScript reaction mix, 0.5 ul of iScript reverse transcriptase, and nuclease free water
to ten microliters. The samples were then incubated as follows: 5 minutes at 25˚C, 30
minutes at 42˚C, 5 minutes at 85˚C, and 10 minutes at 4˚C. Each qPCR reaction was
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performed using 20ng of cDNA. 12.5 ul of 2x Sybr Green Mix (Roche) and 7.5 ul of 1
nM primer mix containing forward and reverse primers (IDT) were used in each sample.
The primer sequences were as follows:
Primers

Forward

Reverse

HLA-E

TTGCAAGGGCCTCTGAATCTGTCT

AGGAACACAGGTCAGTGTGAGGAA

STAT 1α

GTGCATCATGGGCTTCATCAGCAA

TAGGGTTCAACCGCATGGAAGTCA

Cyclophilin AGACAAGGTCCCAAAGACAGCAGA TGTGAAGTCACCACCCTGACACAT
A
p300
TACCAAATGCTGCAGGCATGGTTC TACAAGTCATTCCTGGTTGCGGCT
CBP

TTCGTTGATTGCAAGGAGTGTGGC

TGTTCACTCGGTCTTCCAAGTGGT

PSF

ACAGCGATGTCGGTTGTTTGTTGG

TGGGTGTATCATCCAGTTCGGCTT

HMGA1

ACTTATTGTCCAGGTGAGGCCCAA

AGTGGCGGAAGCAAAGTAGGGTTA

IRF9

TCCATTCAGACATTGGGAGCAGCA

AGATGAAGGTGAGCAGCAGTGAGT

Statistical Analysis
As described in Chapter 2.

Results
The effect of these transcription factors on HLA-E transcription was investigated via
siRNA gene targeting. STAT 1α was used as positive control since it is critical for the
HLA-E interferon response. SKOV3 cells were transfected with siRNA directed against
STAT 1α, PSF, HMGA1, and p300. The percent knockdown for each gene was
determined as well as the overall effect on HLA-E induction by IFN-γ. Gene expression
was normalized by dividing the expression of the target gene by expression of human
Cyclophilin A. Cells were treated for 72 hours prior to stimulation with 200 units/ml of
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IFN- γ. The total knockdown of the target genes in comparison to a scrambled siRNA
control were as follows: STAT 1α expression was decreased by 82% (Figure 39), PSF
expression wad decreased by 66% (Figure 40), HMGA1 expression was decreased by
82% (Figure 41), and p300 expression was decreased by 49% (Figure 42). As
expected there was approximately a 50% reduction in HLA-E induction when STAT 1 α
expression was reduced (Figure 43). However there was no appreciable decrease in
HLA-E induction when PSF, HMGA1, or p300 was knocked down (Figure 43). In the
case of HMGA1 it can be concluded that this transcription factor is not necessary for
HLA-E transcription in SKOV3 cells. However it can be argued that a greater reduction
in p300 or PSF is needed before the effect on HLA-E can be determined.
We also determined the effect of reducing the expression of CBP and IRF9 on HLA-E
induction. SKOV3 cells were transfected with siRNA for 72 hours and then stimulated
with 250 units/ml of IFN-γ. The gene expression was normalized to Cyclophilin A and
compared to a scrambled control. The expression of the p300 family member, CBP,
was only decreased by 33% (Figure 45) but surprisingly resulted in a 54% reduction in
IFN- γ stimulated transcription (Figure 47). Additionally, we reduced IRF9 gene
expression by 76% (Figure 46), resulting in a 43% decrease in HLA-E induction (Figure
47). These results suggest that both CBP and IRF9 could be components of the IRRAC.
Since we were unable to obtain adequate knockdown of p300 and PSF, we wanted to
determine if a shorter siRNA treatment time world allow us to see an effect on HLA-E
induction. We transfected SKOV3 cells with 40 pmol of gene specific siRNA for 48
hours and then stimulated the cells with 200 units/ml of IFN- γ. STAT 1α expression
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was decreased by 92% compared to a scramble control (Figure 48). Endogenous HLAE induction was reduced by 72% compared to wild type (Figure 49). PSF expression
was decreased by 37% which did not have any significant difference in HLA-E induction
(Figure 49 and Figure 51). The expression of p300 was not decreased and had no
effect on HLA-E (Figure 50 and Figure 51).
Therefore the knockdown of p300 was repeated with two new p300 targeting siRNAs.
The first was labeled as p300_95 and the second as p300_97. Once again STAT 1α
was also knocked down to serve as a positive control and a non-specific scrambled
siRNA was used as a negative control. Gene expression was normalized to the
housekeeping gene Cyclophilin A. STAT 1 α was decreased by 88% (Figure 52), p300
expression was decreased by 64% when p300_95 siRNA was transfected, and by 62%
when a combination of p300_95 and p300_97 was used (Figure 53). The total induction
of wild-type samples was 7.2 fold. This increase in transcription was diminished by 67%
when STAT 1 α expression was decreased (Figure 54). Also there was a 32% or 42%
decrease in HLA-E induction when p300_95 or p300_95/97 was used respectively
(Figure 54). This result was interesting because in addition to initial experiments that
suggested that p300 played a role in HLA-E induction, it has also been shown that p300
acetyltransferase activity has helped to increase the transactivation of GATA-1, GATA4, GATA-5 and GATA-6 (Chen 2009, Wada 2000, Kakita 1999, Takaya 2008).
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Figure 39. STAT 1 α expression is decreased by gene knockdown in the SKOV3 cell line.
SKOV3 cells were transfected with gene specific siRNA and nonspecific scramble control for
72 hours prior to 24 hour stimulation with IFN-γ. Gene expression was normalized to
Cyclophilin A.
Seg 1 cells were tranfected with gene specific and nonspecific scramble control for 72 hours
prior to 24 hour stimulation
with IFN-γ.
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Figure 40. PSF expression is decreased by gene knockdown in the SKOV3 cell line. SKOV3
cells were transfected with gene specific and nonspecific scramble control for 72 hours prior
to 24 hour stimulation with IFN-γ. Gene expression was normalized to Cyclophilin A.
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Figure 41. HMGA1 expression is decreased by gene targeting in the SKOV3 cell line.
SKOV3 cells were transfected with gene specific and nonspecific scramble control for
72 hours prior to 24 hour stimulation with IFN-γ. Gene expression was normalized to
Cyclophilin A.
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Figure 42. p300 expression is slightly decreased by gene targeting in the SKOV3 cell line.
SKOV3 cells were transfected with gene specific and nonspecific scramble control for 72 hours
prior to 24 hour stimulation with IFN-γ. Gene expression was normalized to Cyclophilin A.
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Figure 43. Analysis of endogenous HLA-E Expression after gene specific knockdown in
SKOV3. Cells were treated as described in Figures 39-42. Expression was normalized to
human Cyclophilin A. The amount of induction was compared to scramble control.

Endogenous STAT 1 α Expression
Relative Expression

1.2
1
0.8
0.6
0.4
0.2
0
STAT

Scr
(n=3)

Figure 44. STAT 1α expression is decreased by gene targeting in the SKOV3 cell line.
SKOV3 cells were transfected with gene specific and nonspecific scramble control for 72
hours prior to 24 hour stimulation with IFN-γ.
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Figure 45. Effect of CBP gene knockdown in SKOV3 cells. SKOV3 cells were transfected
with gene specific and nonspecific scramble control for 72 hours prior to 24 hour
stimulation with IFN-γ.
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Figure 46. IRF9 expression is decreased by gene knockdown in the SKOV3 cell line. SKOV3
cells were transfected with gene specific and nonspecific scramble control for 72 hours
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prior to 24 hour stimulation with IFN-γ.
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Figure 47. Analysis of CBP and IRF9 Knockdown on HLA-E induction. Cells were treated
as described in Figures 44-46. The amount of induction was compared to scramble
control. Expression was normalized to the Cyclophilin A housekeeping gene.
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Figure 48. STAT 1 α expression is decreased by gene knockdown in the SKOV3 cell line.
SKOV3 cells were transfected with gene specific and nonspecific scramble control for 48
hours prior to 24 hour stimulation with IFN-γ.
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Figure 49. Effect of PSF expression gene knockdown in the SKOV3 cell line. SKOV3 cells
were transfected with gene specific and nonspecific scramble control for 48 hours prior to
24 hour stimulation with IFN-γ.
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Figure 50. Effect of p300 expression gene knockdown in the SKOV3 cell line. SKOV3 cells
were transfected with gene specific and nonspecific scramble control for 48 hours prior to 24
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hour stimulation with IFN-γ.
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Figure 51. Analysis of endogenous HLA-E expression after siRNA knockdown. Cells were
treated as described in Figures 48-50. Expression was normalized to human Cyclophilin A.
The amount of induction was compared to scramble control.
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Figure 52. Effect of STAT 1 α expression gene knockdown in the SKOV3 cell line. SKOV3
cells were transfected with gene specific and nonspecific scramble control for 72 hours prior
to 24 hour stimulation with IFN-γ.
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Figure 53. Effect of p300 expression gene knockdown in the SKOV3 cell line. SKOV3 cells
were transfected with gene specific and nonspecific scramble control for 72 hours prior to
24 hour stimulation with IFN-γ
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Figure 54. Analysis of HLA-E Expression in SKOV3 cells after gene specific knockdown of p300.
Cells were treated as described in Figures 52 and 53. Expression was normalized to human
Cyclophilin A. The amount of induction was compared to scramble control.
Expression was normalized to Cyclophilin A.
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Figure 55. Model of transcriptional regulation on the HLA-E promoter in response to IFN-γ. In the first
panel , we have illustrated a cell line that expresses a GATA transcription family member which has the
ability to recruit CBP or p300 to the transcriptional activation complex. In the lower panel, we have
illustrated a cell line that does not express a GATA factor and also does not recruit CBP or p300. We are also
illustrating the interaction of IRF-9 with the STAT 1 α homodimer.
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Discussion
We previously reported that the Interferon Response Region is a novel interferon
response element consisting of two half sites which are similar to but are not consensus
to the Gamma Activation Site (5’ half) or the Interferon Stimulated Response Element
(3’ half). Despite the lack of homology to known binding sites, each portion of the IRR is
recognized and bound by a STAT 1α homodimer. Thus we hypothesized that additional
proteins may bind to the IRR and facilitate the interaction of the STAT molecules with
the HLA-E promoter. Our laboratory also demonstrated that the interactions of the
activation complex with a radiolabeled IRR sequences is diminished in the presence of
the minor groove binding drugs, Nystatin and Distamycin A. In the present study, we
have attempted to verify potential components of the IRR-AC via gene knockdown
studies.
HMGA1 was the principal factor implicated as a member of the Interferon Response
Region Activation Complex. Using siRNA to target HMGA1 gene expression, we
achieved 82% knockdown of target gene expression. We next examined HLA-E
induction but saw no effect on gene transcription. We also targeted the expression of
PSF, which is another protein that interacts with the minor groove. Target gene
expression was decreased by 66% when treated for 72 hours and by 37% when treated
for 48 hours, but showed no effect on HLA-E transcriptional activation. If either
HMGA1 or PSF were components of the activation complex, we would have expected
to see a similar decrease of HLA-E transcription as when STAT1α expression is
reduced.

91

Previous studies also suggested that the p300/CBP family functions at the HLA-E
promoter. Adenovirus E1a was transfected in to K562 cells to determine the effect of
p300/CBP sequestration on HLA-E induction by IFN-γ. This resulted in a 6-fold
decrease in HLA-E induction and essentially reduced HLA-E promoter CAT activity
measure from the UIRR plasmid to the measurement from the IRR plasmid alone. We
targeted the expression of both p300 and CBP using siRNA. Our maximal knockdown of
p300 expression was 62-65% which caused a 32-42% decrease in IFN-γ stimulation of
HLA-E gene transcription. These results suggest that p300 plays a role in HLA-E
induction and that the mechanism involves p300 acetyltransferase activity. In order to
fully ascertain the effect of p300/CBP on HLA-E induction it is necessary to rule out
compensation from other family members. This can be achieved by performing a dual
knockdown of both p300 and CBP activity. We also slightly decreased the expression
of CBP. Despite approximately a 30% decrease in CBP gene expression there was a
54% reduction in HLA-E induction. This suggests CBP plays a bigger role in HLA-E
induction than p300. Experiments are underway to simultaneously knockdown both
factors.
The ISGF3 protein complex, which consists of STAT1, STAT2, and IRF9, binds to the
Interferon Stimulated Response Element in response to IFN-α or IFN-β. The Interferon
Response Region of the HLA-E promoter consists of two half sites that are similar to the
GAS and the ISRE, respectively. Additionally, it has been shown that IRF9 can
associate with a STAT 1 homodimer and bind to the ISRE in response to IFN-γ
(Bluyssen1996). As a result of these studies we decided to target IRF-9 expression.
We successfully reduced IRF-9 expression by 76% and saw a subsequent 43%
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reduction in HLA-E induction. This observation suggests that IRF9 is able to bind to the
IRR in response to IFN-γ. Future studies will focus on demonstrating IRF9 binding to
the HLA-E promoter.
The Interferon Response Region represents one example of a unique interferon
response element. Other groups have described novel elements as well. A recent
report by Merraro et al describes the ETS/Interferon Response Element (EIRE) in the
promoter of the Interferon Stimulated Gene 15 (ISG15). They show that the ISG15
promoter sequence differs from the classical ISRE element in the MxA, IFN-β, GBP,
and IFN-α genes, which are bound by interferon regulatory factors but not by PU.1. The
ISRE element in the ISG15 gene (5’ CGGGAAAGGGAAACCGAAACTGA3’) is bound
by PU.1, IRF4, and IRF8, therefore the group proposes renaming the sequence as the
EIRE. Furthermore they demonstrate that similar sequences can be found in other
genes such as the human ISG54, p69, and Factor B promoters (2002). Additionally
Marechi et al report a LPS inducible composite PU.1/IRF element that is located in the
IL-1β promoter and is bound by PU.1, IRF4, IRF1, and IRF2 (2001).
Another inducible element was discovered by Weihu et al during their investigation of
IFN-γ stimulation of the IRF 9 gene. The IFN-γ activated transcriptional element
(GATE) is located upstream of the translational start site between the -351 and -1045
bp of the IRF9 promoter (3’ GGGCCTCTCTTAACTTTGAATCCC 5’) and shows no
homology to either the GAS or ISRE. This element was further shown to be activated
by the IFN-γ activated transcriptional element binding factor 1 (GBF1) and C/EBPβ
(Meng 2005). These studies along with our own prove that the concept of interferon
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response elements should be expanded beyond GAS or the ISRE and furthermore that
the protein complexes that interact with these novel sequences do not require STAT.
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Chapter 4: Summary and Future Directions

The goal of this project is to identify molecular targets that cause the differential
induction of Class Ia and Class Ib genes in the presence of IFN-γ. Our interest in HLA-E
centers on the observation that HLA-E has the ability to produce an immune response
that is opposite of that induced by classical MHC molecules. In addition, we have shown
that the promoter of HLA-E differs significantly from that of the Class Ia molecules. We
have demonstrated that the HLA-E molecule responds to interferon gamma via a novel
element termed the Interferon Response Region. Additionally, the induction of HLA-E
can be further increased when an element immediately upstream of the IRR, termed the
upstream interferon response region, is bound by a GATA transcription family member.
Previous studies in our laboratory showed that the action of the upstream element was
dependent upon the IRR. Studies in the K562 erythroleukemia cell line demonstrated
the ability of GATA-1 to bind to the HLA-E promoter in vivo and that siRNA targeting of
GATA caused a decrease in the induction of HLA-E by interferon gamma. Analysis of a
number of other cell lines for UIRR functionality suggested that other GATA family
member could support UIRR function as well.
This led to our hypothesis that all members of the GATA transcription family could
interact with the HLA-E promoter at the UIRR and mediate an increase in HLA-E
expression by interferon gamma. In this work, we wanted to focus on epithelial cells
that would most likely express GATA family members 4, 5, or 6. We detected GATA-6
expression in the Seg 1 and HCT 116 cell lines and demonstrated that induction of
HLA-E could be decreased via specific siRNA gene targeting of GATA-6 in these cell
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lines. The reduction of CAT activity from HLA-E promoter-CAT fusion plasmids with
mutated GATA binding elements further illustrated that GATA factors interact at the
HLA-E promoter. Additionally, overexpression of GATA-4 and GATA-6 in the MeWo
and OvCar 8 cell lines resulted in increased induction of HLA-E in some cases. This
work has demonstrated the importance of GATA transcription factors in the control of
HLA-E expression in specific tumor cell lines.
In this study, we analyzed the expression of GATA factors in various tumor cell lines via
qPCR. We compared the expression of the specific GATA target genes (GATA1-6) to
the expression of the housekeeping gene, Cyclophilin A. We screened hematopoietic
cells, ovarian carcinoma cells, and breast cancer cells for GATA family expression.
K562 cells are an erythroleukemia ell line that was previously demonstrated to express
GATA-1 protein (Barrett et al., 2004) which correlates with our finding of GATA-1
mRNA. This finding is further supported by previous reports describing both GATA-1
and GATA-2 expression in red blood cells (Lowry & Mackay, 2006; Patient & McGhee,
2002; Simon, 1995). A2780 cells are ovarian carcinoma cells that express GATA2 and
GATA5 transcripts. Previous examination of GATA-4 and GATA-6 protein expression in
the A2780 cell line resulted in no detection of protein levels and led Capo-chichi et al to
designate this cell line as “GATA-null” while our findings suggest that A2780 cells are
not “GATA-null” but simply express different GATA factors than examined by this group
(Capo-chichi et al., 2003). Similarly, the ovarian carcinoma, OvCar 8, expressed GATA2 and GATA-6 transcripts. It has been previously reported that GATA factors -2, -4,-5,
and -6 are expressed in the gonads (Viger, Guittot, Anttonen, Wilson, & Heikinheimo,
2008). The evaluation of MCF-7 breast cancer cells demonstrated high levels of GATA96

3 transcript expression. The role of GATA-3 in luminal cell development and the
expression of GATA-3 in white adipocyte precursors in the mammary gland has
previously been described (Chou, Provot, & Werb, 2010; Kouros-Mehr, Kim, Bechis, &
Werb, 2008)
We also examined the expression of GATA factors in colon cancer, esophageal cancer,
pancreatic cancer and skin cancer. We determined that the colon carcinoma, HCT 116,
expressed GATA- 2 and GATA-6 transcripts. Examination of GATA-6 expression in the
gastrointestinal tract demonstrated GATA-6 expression in both the small and large
intestine. Interestingly, the expression of GATA-6 was reduced in colon carcinomas in
comparison to normal epithelium (Haveri et al., 2008). Seg1 cells are an esophageal
tumor cell line that express GATA-2 and GATA-6 transcript. Guo et al examined the
expression of GATA-4, -5, and -6 in esophageal carcinomas and determined that
GATA-6 expression was detectable via qPCR. However, GATA-4 and GATA-5 were
not detectable and this lack of expression was a result of promoter hypermethylation of
both of these genes (Guo et al., 2006)). We observed expression of GATA-4 and
GATA-5 in Panc-1 cell line. This observation is supported by reports of GATA-4 and
GATA-5 message in human pancreatic carcinomas (Fu et al., 2007). Our examination
of GATA expression in the MeWo cell line revealed very low levels of GATA-6 transcript
which is a novel finding.
Our observation of GATA-2 expression was the only finding that did not seem to
correlate with previous observations in the literature. GATA-2 transcript was detected in
several cell lines with the highest level of expression occurring in K562 erythroleukemia
cells. The other positive cell lines were MCF-7 (breast carcinoma), SKOV-3 and OvCar
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8 (ovarian carcinomas), Tera-2 (embryonal carcinoma), Panc-1 (pancreatic carcinoma),
and MeWo (melanoma). Expression in the cell lines besides K562 may be example of
aberrant protein expression in tumor cells since these tissues are mesoendodermal in
nature and therefore would be expected to express GATA-4, -5, or -6. Interestingly, the
expression of GATA-2 in these cell lines in comparison to K562 was at least 8-fold
lower. It is necessary to examine each cell line for GATA-2 protein expression to
determine if the low levels of GATA-2 transcript leads to GATA-2 protein.
We investigated the effect of GATA overexpression on UIRR functionality of the HLA-E
promoter by transfecting the MeWo cell line with GATA-4, GATA-6, or both GATA-4 and
GATA-6. Interestingly, we observed a decrease in pigmentation in cells that
overexpressed GATA transcription factors as compared to wild-type. This decrease in
color suggests de-differentiation of the MeWo cells. Similarly, overexpression of GATA3 in white adipose tissue resulted in cellular arrest at the preadipocyte stage while
downregulation of GATA-3 allowed progression from the preadipocyte stage to the
adipocyte stage (Chou et al., 2010) Furthermore, Tong et al showed that GATA-3
controls the preadipocyte-adipocyte developmental transition by suppressing the
expression of the peroxisome proliferator activated receptor gamma (PPAR- γ) gene
expression. The expression of other molecular markers of adipogenesis such as Glut-4
and adipocyte fatty acid bind protein AP2 were also decreased in comparison to vector
transfected controls (Tong et al., 2000)
In addition to screening the tumor cell lines for GATA mRNA expression, we also
investigated the UIRR functionality in these cell lines using HLA-E promoter driven CAT
reporter gene assays. Based on our findings we can conclude that expression of a
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GATA transcription factor family member is necessary but not sufficient to cause an
enhanced response in HLA-E transcription after IFN-γ treatment. We have observed
this in the case of the ovarian carcinoma, Hela, and the pancreatic carcinoma, Panc -1
cell line. Hela cells have been shown to express GATA-2 and Panc-1 has been shown
to express GATA-5. While it is tempting to speculate that these GATA-2 and GATA-5
are incapable of mediating UIRR function, UIRR activity was observed in the A2780 cell
line, which expresses both of these factors. A possible explanation is that the GATA-2
and GATA-5 expressed in Hela and Panc-1 cells, respectively, are altered in some way
or lack required cofactors and thus lack the ability to interact with the HLA-E promoter.
Future experiments should include isolation and cloning of the specific GATA family
member expressed in Hela or Panc-1 to determine if the proteins are truncated or are
unable to bind to the HLA-E promoter. This could also be evaluated by the
overexpression of a GATA family member in these cells. However previous attempts
made by our laboratory to overexpress GATA-1 in Hela cells proved to be unsuccessful.
Another intriguing possibility is the analysis of cofactors that may be interacting with
GATA family members bound to the UIRR. Interaction with other transcription factors,
co-activators, or co-repressors can modulate the activity of GATA transcription factors.
Furthermore, GATA transcription factors have been reported to interact with several
different proteins. One of the best characterized associations is that between the GATA
factor family and the Friend of GATA (FOG) family, which consists of FOG-1 and FOG2. The FOG proteins can act as either activators or repressor of GATA activity. Tsang
et al first described FOG-1 as a nuclear zinc finger protein that demonstrated a similar
pattern of expression as GATA-1 (fetal liver, yolk sac, spleen, liver, and testis) and was
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critical for erythroid cell and megakaryocyte differentiation ((Tsang et al., 1997)(Robert,
Tremblay, & Viger, 2002).
FOG-2 shares a similar protein structure with FOG-1, but has a divergent primary
structure (Tevosian et al., 1999). FOG-2 is expressed in the heart, brain, testis, and
ovaries and, like FOG-1, interacts with GATA factors via the N-terminal zinc finger.
FOG-2 null mice die from defects in heart morphogenesis and coronary vascular
development (Tevosian et al., 1999). Based upon expression, it has been shown that
FOG-1 interacts mainly with GATA-1 and GATA-2, while FOG-2 interacts with GATA-4
and GATA-6. However, it is important to note that both FOG family members can
interact with all GATA family members. When studying the transcriptional role of FOG
proteins in gonadal cells, Robert el al used gene reporter assays in conjunction with
transient overexpression of GATA-1, GATA-2, GATA-4, and GATA-6 along with either
FOG-1 or FOG-2 to demonstrate that both FOG-1and FOG-2 repressed GATA activity
at GATA dependent gonadal promoters (2002).
Additionally, there is a well known antagonistic relationship between GATA-1 and PU.1,
GATA-2 and C/EBPα, and GATA-3 and T-bet. In each case, the importance is centered
on the development of hematopoietic cells and is actually concentration dependent. For
example, in the case of GATA-1 and PU.1, overexpression of GATA-1 in
myelomonocytic cells resulted in transformation into eyrthroid, megakaryocytic, and
eosinophilic cells (Rekhtman et al., 2003). Furthermore, the ability to of PU.1 to
negatively regulate GATA-1 activity was illustrated by Moreau-Gachelin et al, who
showed that the transgenic overexpression of PU.1 in erythroid cells results in
increased rates of erythroleukemia development (1996). The mechanism of this
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inhibition has also been evaluated. PU.1 has been shown to physically interact with
GATA-1 in mouse erythroleukemia cells (Burda et al., 2009). Amino acids in the Cterminal domain of PU.1 are required to bind to GATA-1, while the N-terminal domain is
needed to block GATA-1 binding to DNA (P. Zhang et al., 2000). Although no such
antagonistic relationship has been reported with the GATA 4, 5, or 6 family members, it
would be interesting to investigate if such a phenomenon is occurring in the Hela or
Panc-1 cell lines. It would also be interesting to determine if there is competition
between a cofactors and GATA family member in cell lines which did not support UIRR
function.
The ultimate goal of this work is to determine how to control HLA-E expression
independently of other MHC molecules. We have previously shown that induction of
HLA-E by interferon gamma is contingent upon activity at the IRR. Thus it is imperative
to understand all components and characterize the proteins that interact with the IRR
and the UIRR following interferon gamma stimulation. Although we have already
demonstrated that STAT 1 alpha homodimers bind to the Interferon Response Region,
there is evidence to suggest that other proteins may also be necessary for the full
induction of HLA-E transcription. The Interferon Response Region is composed of an
extended, imperfect inverted repeat consisting of two distinct half sites. However,
neither the 5’ half or the 3’ half represent consensus STAT binding sites. These
nonconsensus binding sites as well as the AT rich nature of the interferon response
element led to the hypothesis that STAT 1 alpha was not acting alone at the HLA-E
promoter. Since minor groove binding proteins interact with AT rich stretches of DNA
and have the ability to change the architecture of DNA, we investigated the possibility of
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minor groove binders such as HMGA1 or PSF as components of the IRR-AC. Based
upon preliminary experimental results, both proteins seemed like putative candidates.
HMGA1 was implicated via electrophoretic mobility shift assay via both oligonucleotide
competition of the IRR-AC and by ablation of the complex that bound to the radiolabled
IRR probe after incubation of stimulated U937 nuclear extracts with antibody specific for
HMGA1. However, PSF, not HMGA1, was identified along with STAT 1 alpha in
biochemically purified IRR binding complexes. However specific siRNA knockdown of
both PSF and HMGA1 gene expression showed no effect on HLA-E induction. It is
important to note that a subsequent purification attempt did show several small
molecular weight bands that were not able to be identified by the mass
spectrophotometry analysis. Thus, it is possible that another protein with minor groove
binding capabilities can interact with the IRR.
In the future it will be necessary to purify the complex that binds to the Interferon
Response Region in order to elucidate the components of the IRR-AC. Previous
attempts to purify the complex consisted of a three-step purification strategy that utilized
successive anion exchange columns followed by a DNA affinity column. It may prove
useful to investigate a strategy that provides higher purification yields in order to identify
any low abundant proteins that may be a part of the complex. This could be achieved
by implementing a double affinity purification strategy. Briefly, a recombinant STAT 1
protein that is tagged with a V5 epitope can be generated and expressed in Hela S3
cells. Therefore the initial purification step will utilize the specificity of anti-V5 antibody,
whereas the subsequent step will use DNA affinity chromatography.
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The discovery of a component of the IRR-AC that is specific for HLA-E induction and is
required for the HLA-E interferon gamma response in all cell types, as opposed to the
cell type specific response mediated by GATA transcription family members is needed
for specific HLA-E modulation. MATInpsector analysis of the IRR promoter region
suggested that IRF-4 could interact with this portion of the HLA-E promoter. However,
IRF-4 expression is restricted to T-cell and B-cell lineages. As we stated previously, the
Interferon Regulatory Factor family share a conserved DNA binding domain. Therefore,
the information from this program suggested that an interferon regulatory factor could
potentially interact at the IRR. Examination of the literature revealed that IRF-9 has
been shown to form a heterotrimer with a STAT 1α homodimer or with a STAT1/STAT2
heterodimer in response to interferon. Based upon these findings, we decided to
evaluate the involvement of IRF-9 in the transactivation of the HLA-E gene. We used
siRNA specific gene targeting to decrease IRF-9 expression and observed a
concomitant decrease in HLA-E induction. This result is particularly intriguing because
it shows that the same factor can be involved in the transcriptional regulation of both
classical MHC and nonclassical MHC in response to different interferon types. As
stated previously, IRF-9 interacts with STAT1 and STAT2 in response to IFNα/IFNβ
signaling. A different family member, IRF-1, mediates the classical MHC response to
IFN-γ. However in the case of HLA-E, we have demonstrated that IRF-9 helps to
mediate the response to IFN-γ. Therefore in the context of IFN-γ signaling, the
differential regulation of MHC could possibly be achieved by targeting IRF-9 expression.
Further studies are required to ensure that a decrease in IRF-9 has no effect on the
induction of Classical MHC in response to IFN-γ. Finally it would be interesting to
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determine the functional consequence of controlling the expression of the HLA-E
molecule on the surface of target cells and the subsequent ability of Natural Killer cells
and CD8 + T cells to destroy the targets in cytolytic assays. Since HLA-E serves as the
principal ligand for the NKG2A/CD94 receptor that is present on many natural killer
cells, NK-T cells, and a subset of cytotoxic T lymphocytes, the ability to regulate this
gene has the potential to have a major impact on adoptive immunotherapy and bone
marrow transplantation.
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